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1. INTRODUCTION 
Metabolomics concerns with the measurement and analysis of small molecule 
compounds (< 1 kDa, e.g. amino acids, biogenic amines, carbohydrates, fatty 
acids, nucleic acids, peptides) of both exogenous and endogenous origins. These 
are the substrates and products of various chemical reactions within metabolic 
pathways (Cajka and Fiehn 2016). The simultaneous measurement of these 
compounds provides a direct reflection of the metabolic network – the so-called 
“metabolic fingerprint”, which provides the information about the status of the 
biological system in question (Kosmides et al. 2013). Due to the comprehen-
siveness of metabolomics it is widely used in biomedical sciences to study 
various diseases like cancer (Jové et al. 2017; Uchiyama et al. 2017; Bachmayr-
Heyda et al. 2017), cardiovascular diseases (Guasch-Ferré et al. 2017; García-
Fontana et al. 2016), diabetes (Murfitt et al. 2018; Niewczas et al. 2017; 
Brugnara et al. 2012) and many others (Yilmaz et al. 2017; Trezzi et al. 2017; 
Naz et al. 2017). Overall, the methods used in metabolomics have been 
invaluable to many fields of science and have provided multiple disease-specific 
markers to help with the better diagnosis and treatment of diseases. 
Psoriasis (PS) is a widespread chronic inflammatory skin disease affecting 
2%–3% of the population in the world (Parisi et al. 2013). The disease is con-
sidered to be multifactorial with a number of key contributing factors including 
genetic predisposition and susceptibility, environmental influences along with 
immune dysfunction and the disruption of the skin barrier (Raychaudhuri, 
Maverakis, and Raychaudhuri 2014). Psoriasis onset usually starts between the 
ages of 20–30 years and/or a later onset at 50–60 years (Cameron and Van 
Voorhees 2014; Perera, Di Meglio, and Nestle 2012) The five subtypes of 
psoriasis are erythrodermic, guttate, inverse, pustular and vulgaris (plaque) of 
which the latter is the most common affecting up to 90% of psoriatic patients 
(Griffiths and Barker 2007). In addition to the effects on the skin, psoriasis 
bestows noticeable psychological distress and impairment, which often results 
in an adverse impact on the quality of the patient’s life (Chapman and Moynihan 
2009; Steven R. Feldman, Malakouti, and Koo 2014). The disease can have a 
negative social influence in the workplace manifesting as discrimination and 
challenge in finding employment. Absence from work over the previous year 
has been reported in up to 60% of patients with psoriasis (S. R. Feldman et al. 
1997). Psoriatic arthritis (PsA), which is a chronic, progressive inflammatory 
arthritis affects 6% to 41% of psoriasis patients (Ogdie and Weiss 2015). 
Approximately 40% of patients with skin psoriasis have nail disease while in 
patients with PsA the rate increases up to 80% (Sobolewski, Walecka, and 
Dopytalska 2017). As an added risk factor, psoriasis contributes to numerous 
concurrent physical comorbidities like diabetes, cardiovascular disease, inflam-
matory bowel disease, metabolic syndrome, and obesity; all leading to decreasing 
longevity (Armstrong, Gelfand, and Garg 2014; J. M. Gelfand and Yeung 2012; 
Kimball et al. 2008; Love et al. 2011) or even death (Pearce et al. 2006).  
Atopic dermatitis (AD) is a widespread and complex condition that affects 
up to 15% adults and children worldwide. Although children have an increased 
prevalence of atopic dermatitis, many adults remain affected throughout their 
life (Abuabara and Margolis 2013). The pathogenesis of AD is multifactorial 
combining skin barrier dysfunction and immune system dysregulation 
(Czarnowicki, Krueger, and Guttman-Yassky 2014; Barton and Sidbury 2015) 
in addition to higher odds of developing AD in patients who were overweight or 
obese (Zhang and Silverberg 2015). The clinical forms of adulthood AD are 
divided into the following categories although commonly they appear together: 
head-and-neck eczema, hand eczema, generalized eczema, nummular eczema, 
erythroderma, nodular prurigo, lichen simplex, psoriasiform dermatitis and 
miscellaneous (Salvador, Romero-Pérez, and Encabo-Durán 2017). As is with 
psoriasis, the skin effects of the disease have a severe impact on the quality of 
life of the patients, which in turn places a burden on the economy (Drucker, 
Wang, and Qureshi 2016). Comorbidities of AD range from the long-associated 
food allergies, asthma and hay fever, while more recent data has expanded the 
list to attention deficit-hyperactivity disorder (Pelsser, Buitelaar, and Savelkoul 
2009; Riis et al. 2016; O’Brien and Jones 2013) and anemia (Drury, Schaeffer, 
and Silverberg 2016).  
Atherosclerosis is classified as an inflammatory disease that involves the 
arterial wall and is characterized by the continuous accumulation of inflam-
matory cells and lipids within the intima of large arteries (Badimón, Vilahur, 
and Padró 2009). Given that the pathological process endures and macrophages 
do not remove cholesterol that is accumulated in the vessel, they become 
apoptotic, which in turn causes the release of cholesterol, metalloproteinases and 
prothrombotic molecules to the wall of the vessel (Ghosh et al. 2010). Plaque 
disruption and the following exposure to thrombogenic substrates initiates the 
adhesion, activation and aggregation of platelets on the surface of the vascule, 
which in turn activates the coagulation cascade. This, through thrombus 
activation, leads to the clinical manifestation of the atherosclerotic disease, acute 
myocardial infarction or sudden death (Vilahur and Badimon 2013; Legein et al. 
2013). The most common clinical manifestations of atherosclerosis are peripheral 
arterial disease (PAD) and coronary arterial disease (CAD), both of which have 
been noted as major public health problems (Criqui and Aboyans 2015; Wong 
2014). 
Psoriasis and atopic dermatitis have both been associated with cardiovascular 
diseases (CVD) (Prey et al. 2010; Standl et al. 2017). The exact correlations of 
PS and AD with CVD is not fully understood yet although it can be hypo-
thesized that the chronic inflammation prevalent in both diseases leads to the 
loss of elasticity of arteries through atherosclerosis, which in turn increases the 
risk odds for stroke and myocardial infarction (MI) (Dattilo et al. 2018; Brunner 
et al. 2017).  
In the present thesis the metabolomic profiles of patients with psoriasis and 
atopic dermatitis were explored to find possible disease-specific metabolites that 
could be used to characterize and better understand the underlying mechanisms 
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of the disease pathogenesis. Since both skin conditions have been associated 
with cardiovascular diseases (Dattilo et al. 2018; Radner et al. 2017; Standl et 
al. 2017; Brunner et al. 2017), the application of the established methods was 
expanded to peripheral arterial disease and coronary arterial disease to further 
search for similarities and differences in the metabolomic profiles of the 
diseases.  
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2. REVIEW OF THE LITERATURE 
2.1. Metabolomics 
Metabolomics (also called metabonomics) is among the latest of the so-called 
“omics” research fields and it focuses on the intermediates and products of 
metabolism including amino acids, antioxidants, biogenic amines, carbohydrates, 
fatty acids, nucleotides, organic acids, vitamins and many others. The term 
“metabolome” is analogous to the “proteome” and “transcriptome”, and describes 
the complete set of metabolites, both endogenous and exogenous, present in a 
biological system and it can be depicted on all the levels of biological complexity: 
organisms, tissues, cells and cell compartments (Nicholson and Lindon 2008). In 
comparison to the amount of proteins, genes and transcript isoforms the number 
of metabolites present in humans is relatively small with an estimated size of 
8000, but since the metabolome is very dynamic and more susceptible to natural 
fluctuations and external stimuli, it characterises the final response of an 
organism to genetic alterations, gut microflora and the environment extremely 
well (Holmes, Wilson, and Nicholson 2008; Vermeersch and Styczynski 2013). 
This in turn explains the rise in popularity of metabolomics methods used in 
research. 
 
 
2.1.1. Analytical techniques in metabolomics 
Currently, three different techniques are used in metabolomics: metabolomic 
fingerprinting, metabolite profiling and targeted metabolomics. In the first 
approach the identification of metabolites is not necessary since the goal of 
fingerprinting is to represent various classes of compounds that might be 
interesting to the study. This technique is used primarily for the classification of 
a sample (case/control) since it does not use exhaustive sample pre-preparation 
or advanced chromatographic separation techniques and the measured meta-
bolites are not known a priori (Drexler, Reily, and Shipkova 2011; Blekherman 
et al. 2011). Metabolite profiling aims to identify and quantify as many meta-
bolites as possible. The compounds are not known beforehand and therefore 
require high-resolution chromatographic separations with precise mass spectro-
metry detection. Metabolite profiling enables the detection of novel compounds 
and the metabolic pathways they are associated with, thus often leading to the 
conceptualization of new scientific hypotheses (Blekherman et al. 2011; 
Schuhmacher et al. 2013). In the case of targeted metabolomics, the measured 
compounds and their retention time windows are known beforehand thus 
enabling the precise quantification of the metabolites of interest. These are 
usually selected based on their biological availability, metabolic pathways of 
interest or their potential as a biological marker for a disease. Sample prepa-
ration procedures usually involve derivatization and adding of isotopic internal 
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standards. Chromatographic separations are also included in most cases (Zhou 
and Yin 2016).  
Two of the most widely used analytical platforms used in metabolomics are 
mass spectrometry and nuclear magnetic resonance (NMR) of which 1H-NMR 
is the most common (Spratlin, Serkova, and Eckhardt 2009; Gika et al. 2014) to 
analyze a multitude of small coexisting molecules with either of these techni-
ques, including metabolite identification and quantitation. Both however have 
their own strengths and limitations. The use of mass spectrometry usually 
necessitates the use of a separation technique for biological fluids thereby high 
resolution techniques are applied including capillary electrophoresis (CE), gas 
chromatography (GC) or liquid chromatography (LC) (Gika et al. 2014; Putri et 
al. 2013; Lenz and Wilson 2007; Ban et al. 2011) CE enables the analysis of 
polar, ionic molecules. The main advantage of this technique is the excellent 
separation capacity while low repeatability remains as the major limitation of 
CE. While using GC the compounds are heated to the gas state, which is why 
non-volatile substances require the use of derivatization prior to use. LC on the 
other hand provides the possibility to analyze a wide range of metabolites 
ranging from hydrophobic to hydrophilic. Since the introduction of ultra-high 
performance liquid chromatography (UHPLC), increased peak capacity, reduced 
time of analysis and higher sensitivity has been achieved through the use of 
smaller particles in columns and higher pressures in LC (Gika et al. 2014; Putri 
et al. 2013; Lenz and Wilson 2007). The use of NMR spectroscopy provides 
other advantages including minimal preparation of samples and the non-depen-
dence on analyte separation. Since the use of NMR does not ruin the sample, it 
can be recovered and reused in future studies. This makes NMR ideal for the 
analysis of biopsies and cell samples. Furthermore, when compared to MS the 
intensity of the NMR signal is not so greatly affected by the matrix components 
of a sample. This makes NMR a very appropriate tool for the analysis of very 
complex biological samples. However, one drawback of NMR is its low sensi-
tivity, thus requiring a larger amount of sample (Bu et al. 2012; Putri et al. 
2013).  
 
 
2.1.2. Statistical techniques in metabolomics 
The analysis of data acquired from MS and NMR measurements can be divided 
in two: the pre-processing and the statistical analysis.  
The pre-processing of MS data includes peak picking – each measured ion is 
detected and assigned to a feature (mass-to-charge ratio (m/z) / retention time 
(RT) pair) and smoothed where necessary using vendor software; alignment – 
due to the changes in the column stationary phase and the mobile phase, RT shifts 
occur and are aligned using alignment algorithms (Mitra et al. 2018); gap 
filling – badly-shaped peaks can cause missing values, which are corrected 
using raw data and algorithms (Hrydziuszko and Viant 2011); quality control 
(QC) correction – when analyzing a large number of samples the use of pooled 
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samples from all study samples are used, called QCs. These are applied to 
ensure the correction of intensity drifts and repeatability of measurements 
(Dunn et al. 2011; Kamleh et al. 2012). The pre-processing of 1H-NMR experi-
ment data are usually automated by the instrument’s vendor software and 
include apodization, baseline correction, Fourier transform, chemical shift 
calibration and phasing. After the pre-processing of data is complete a data 
matrix is generated where rows correspond to the study samples while spectral 
data points are stored in columns. 
The statistical analysis of the acquired and pre-processed data usually starts 
with principal component analysis (PCA), which is an unsupervised linear 
mixture model. The main advantage of PCA is that it takes the whole dataset as 
input and calculates new principal components (PCs) in a way that they are 
pairwise orthogonal (i.e. decorrelated) to each other and reordered by the amount 
of variance explained. The newly calculated PCs can then be used to visualize 
the clustering and sample group discrimination of data (Lindon, Holmes, and 
Nicholson 2006; Tharwat 2016). Similarly, other unsupervised multivariate 
methods like ANOVA-simultaneous component analysis (ASCA) (Smilde et al. 
2005), hierarchical cluster analysis (HCA) (Smilde et al. 2005; Beckonert et al. 
2003) and k-means clustering (Hageman et al. 2006) can be used. Supervised 
linear mixture models, i.e. where the response variable (class of sample in case-
control study) is specified include partial least squares discriminant analysis 
(PLS-DA) (Hageman et al. 2006; Boulesteix and Strimmer 2007), orthogonal-
PLS (Trygg and Wold 2002). These methods are useful when the classification 
of samples is needed, however the results are often prone to overfitting 
(Broadhurst and Kell 2006), which can be overcome by including certain 
validation techniques like bootstrapping (Wehrens, Putter, and Buydens 2000) 
or cross validation (Westerhuis et al. 2008). Machine learning methods for the 
classification of samples include random forest (RF) (Breiman 2001), support 
vector machine (SVM) (Burges 1998), and elastic net regression (Zou and 
Hastie 2005) among many others (Tibshirani 1996; Hoerl and Kennard 2000; 
Trygg and Wold 2002). For hypothesis testing, which is central in the analysis 
of metabolomics data, metabolite intensities are compared between cases and 
controls. If the data is normally distributed a Student’s t-test can be used or 
Mann-Whitney Wilcoxon test when the data does not follow a normal distri-
bution. When two or more conditions are compared, an analysis of variance 
(ANOVA) or Kruskal-Wallis test can be used for normally or not-normally 
distributed data respectively. Regardless of the test used, most metabolic studies 
consist of a great number of metabolic features and therefore the calculated p-
values need to be adjusted for multiple hypothesis testing. Two of the most 
widely used include the Benjamini and Hochberg (Benjamini and Hochberg 
1995) and the stricter Bonferroni correction (Goodier 2007). 
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2.2. Psoriasis overview 
Plaque psoriasis is an immune-mediated inflammatory skin disease that is cha-
racterised by red, scaly and distinct skin plaques, which result from the hyper-
proliferation of keratinocytes in addition to inflammatory cell infiltration and 
neovascularization (Nestle, Kaplan, and Barker 2009). Experimental and clinical 
evidence point to the immune system having a central role in the pathogenesis 
of the disease. The disease can be triggered in genetically susceptible indi-
viduals by numerous factors that include infection (e.g. streptococcal), medi-
cations (β-blockers, IFNα and lithium) and trauma (Goldsmith et al. 2012). The 
initiation phase involves the activation of dermal dendritic cells by activated 
plasmacytoid dendritic cells. This in turn activates T helper (Th) and cytotoxic 
T cells that are essential in the maintenance of the disease (Nestle, Kaplan, and 
Barker 2009). Th1, Th17 and Th22 all contribute to the disease by the continued 
production of cytokines. (Di Meglio et al. 2011). IL-17A is responsible for both 
of these processes (Suzuki et al. 2014). A chronic inflammatory phase follows 
the initiation phase and is sustained by amplification signals and feedback 
loops. These key mediators include cationic proteins, antimicrobial peptides and 
members of the innate immune system such as pro-inflammatory chemokines 
and cytokines (for example, TNF, IL-17, IL-22 and CC-chemokine ligand 20 
(CCL20), among numerous others), cathelicidin antimicrobial peptide (CAMP) 
and angiogenic factors (Lande et al. 2007). Psoriasis is subdivided into 
erythrodermic, guttate, inverse, pustular and vulgaris (plaque) (Griffiths and 
Barker 2007) of which the latter is the most common. Psoriatic arthritis (PsA) 
affects 6%–41% of patients with psoriasis (Joel M. Gelfand et al. 2005; Reich et 
al. 2009; Mease et al. 2013) and the onset of PsA is between the ages of 35 and 
45 whereas men and women are affected equally. In most cases the onset of 
arthritis happens roughly 10 years after the onset of psoriasis, however in 15% 
of patients arthritis develops before any noticeable changes in the skin happen. 
Currently there haven’t been noted any correlations between the severity of skin 
and joint manifestations (Gladman et al. 2005). In addition to PsA, psoriasis 
patients have been noted to have an increased prevalence of systemic and 
vascular inflammation along with clinical atherosclerosis (Ahlehoff et al. 2013). 
 
 
2.2.1. Psoriasis biomarkers 
A biomarker is defined as a biological characteristic that can be measured and 
evaluated objectively as an indicator of normal and pathogenic biological 
processes or pharmacological response to therapeutic treatment (“Biomarkers 
and Surrogate Endpoints: Preferred Definitions and Conceptual Framework” 
2001). Biomarkers can also be used to pinpoint disease risk factors, which 
consequently can lead to an improved understanding of the pathogenesis of a 
disease. The best possible biomarker is sensitive, specific, reproducible, accurate 
and predictive. The detection method on the other hand must be standardised, 
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robust and easy to perform. In clinical practise, if a test for a biomarker is to be 
used, the sensitivity and specificity have to be ≥ 0.9 (Søreide 2009).  
Plaque psoriasis is a multifactorial disease and the search for reliable bio-
markers has spanned over multiple fields of research. In genetics for example 
guttate and early onset psoriasis are associated with psoriasis susceptibility 
region 1 (PSOR1) (Hébert et al. 2012), but due to the heterogeneity of the 
disease, no single mutation can be attributed to psoriasis. Instead, a wide range 
of single nucleotide polymorphisms (SNP) that are in part responsible have 
been detected using genome-wide association studies (Tsoi et al. 2012). In 
addition, psoriasis-associated genes have been noted in areas that are closely 
related to the function of the skin barrier (e.g. LCE3B/3C), nuclear factor κB 
pathway (e.g. NFKBIA), type I interferon (IFN) induction (e.g. IFHIH1) and 
Th17 cell activation (e.g. IL23R) (Tsoi et al. 2012; Capon and Barker 2012). 
Most of the named genes are involved in inflammatory and immunological 
processes, which further supports the immune system’s central role in psoriasis 
pathogenesis. Protein analysis has yielded many pro-inflammatory cytokines 
including TNF, IFN-γ, IL-6, IL-8, IL-12 and IL-18 (Arican et al. 2005). 
Additionally patients with psoriasis exhibited unusual levels in blood fibrino-
lysis and coagulation, such as increased levels of fibrinopeptide A, fibrinogen, 
D-dimer and C4, and decreased levels of alpha 2-antiplasmin, protein C, and 
plasminogen (Marongiu et al. 1994). Regarding the metabolomics of psoriasis, 
lower metabolite levels of glucose and myoinositol were noted while higher 
levels of taurine and choline were found in tissue biopsies from psoriatic skin 
when compared to non-lesional skin (Sitter et al. 2013). In other studies 
psoriasis patients were found to exhibit higher levels of alpha ketoglutaric acid 
(AKG) and lignoceric acid, and lower levels of asparagine and glutamine, while 
patients with both psoriasis and psoriatic arthritis had a decreased level of AKG 
(Armstrong et al. 2014). Another study found significant psoriasis-associated 
changes in three metabolic pathways that included multiple amino acids: 
1) aspartate, alanine, and glutamate, 2) glycine, threonine, and serine, 3) proline 
and arginine. Post treatment with the anti-TNFα drug Etanercept, a large part of 
psoriasis-associated changes in circulating metabolites were reversed, thus 
shifting the metabolic profiles of psoriasis patients closer to that of controls 
(Kamleh et al. 2015). 
 
2.3. Atopic dermatitis overview 
Atopic dermatitis (AD) or atopic eczema is a widespread disorder of the skin 
that has a multifactorial pathophysiology. AD usually develops before the age 
of 5 in 85% of patients and usually clears by adolescence. In some patients 
however the disease can persist into adulthood (Wüthrich 1999). In western 
countries AD is one of the most common skin diseases that affects up to 1% to 
3% of adults and up to 20% of children (Williams et al. 1999). AD develops in 
individuals that have a genetic predisposition and experience exogenous 
provocation factors. More precisely, the barrier defects in the epidermis and the 
dysregulation of the innate and adaptive immune systems are thought to be the 
cause (Lodén 2003). The abnormalities in the skin barrier are the result of 
multiple factors including microorganisms, exposure to chemicals (Nowicka 
and Grywalska 2018), and low humidity and temperature (Heimall and Spergel 
2012). Since the prevalence of AD has been on the rise (Broberg et al. 2000) it 
is thought that environmental factors have a greater effect on the outbreak of the 
disease rather than the genetic background (Taïeb 1999). In the study of the 
pathogenesis of atopic dermatitis multiple genes have been discovered to play a 
role; these include interleukin (IL)-4, the receptor of IL-4 and IL-13 (He et al. 
2003; Liu et al. 2000). The strongest association for a candidate gene for atopic 
eczema has been shown in multiple studies to be for the gene encoding filaggrin 
(FLG) (Irvine, Irwin McLean, and Leung 2011; Palmer et al. 2006; Rodríguez 
et al. 2009). This filament aggregating protein is expressed in the epidermal 
granular layer and binds to keratin fibers in epithelial cells. Its functions include 
the contribution of acidic and hygroscopic amino acids to the stratum corneum, 
in addition to antimicrobial effects (Brown and McLean 2012). Th-2 (IL-4/IL-
13/IL-25) and Th22 (IL-22) cytokines are noted to be increased in AD and they 
suppress the expression of filaggrin in keratinocytes (Gutowska-Owsiak et al. 
2011; Hvid et al. 2011; Pellerin et al. 2013). This in turn might cause the barrier 
defects in skin. Thereby it is hypothesized that barrier dysfunction is triggered 
by immune activation through a positive feedback loop (Leung and Guttman-
Yassky 2014). Additionally the skin lesions of atopic eczema have epidermal 
hyperplasia, accompanied by large T-cell and dendritic infiltrates, which leads 
to an increased production of inflammatory intermediates (Guttman-Yassky, 
Nograles, and Krueger 2011). AD has the following clinical subtypes although 
commonly they appear together: head-and-neck eczema, hand eczema, gene-
ralized eczema, nummular eczema, erythroderma, nodular prurigo, lichen 
simplex, psoriasiform dermatitis and miscellaneous (Salvador, Romero-Pérez, 
and Encabo-Durán 2017). AD has a range of comorbidities ranging from the 
immunoglobulin E (IgE) mediated hay fever, asthma and food allergy (Silver-
berg and Simpson 2014; Fölster-Holst et al. 2006) to sleep disturbance (Bender, 
Leung, and Leung 2003), depression (Yu and Silverberg 2015), obesity 
(Silverberg et al. 2015), lipid abnormalities and atherosclerosis (Ewald et al. 
2015; Hjuler et al. 2015)  
 
 
The need for biomarkers for atopic dermatitis is evident because the disease is 
highly heterogeneous. AD has been classified as extrinsic (allergic, high total 
serum IgE levels) or intrinsic (non-allergic, normal total IgE). The classification 
models also associate T-cell activation with AD, particularly Th2/Th22 polari-
zation, with a Th1 component in patients with chronic AD and a possible 
contribution of Th17 (Gittler et al. 2012). This indicates that higher levels of the 
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Th2 cytokines IL-4 and IL-13 in AD skin lesions could influence immuno-
globulin class-switching, promoting excessive IgE production (Poulsen and 
Hummelshoj 2007; Oettgen and Geha 1999). It has been demonstrated however 
that both groups showed similar expression levels in Th2-related genes, which 
suggest an overlap in the underlying pathomechanisms (Suárez-Fariñas et al. 
2013). Therefore, to further search for biomarkers, it would be useful to charac-
terise the diversity in pathogenesis of patients with atopic eczema. Currently no 
reliable biomarkers for diagnosis or prediction for the onset of the disease exist 
(Thijs, de Bruin-Weller, and Hijnen 2017), although various markers exist for 
screening, prognostic, pharmacodynamic and monitoring purposes including the 
filaggrin gene (Kezic et al. 2011), IgE (Peters et al. 2010), and transcriptomic 
changes (Tintle et al. 2011), among others (Staudacher et al. 2015; Kim et al. 
2016). The metabolomics research on AD patients has revealed changes with 
inflammatory response, bile acid metabolism, energy metabolism disorder 
(Huang et al. 2014), unbalance in multiple pathways of systemic metabolism 
(Assfalg et al. 2012) and altered serum lipid metabolism (Agrawal et al. 2018).  
 
 
 
 
2.4. Atherosclerosis overview 
Atherosclerosis is the narrowing of the arteries due to the buildup of plaque in 
the innermost layer of the artery, the intima. The plaques consist of connective-
tissue elements, cells, lipids and debris (Stary et al. 1995). The thickening of the 
arterial wall can lead to blood flow disrupture – stenosis, but angiographic 
studies have identified that in most cases infarction occurs due to the formation 
of occluding thrombus on the surface of the plaque (Davies 1996). Thrombosis 
can occur either when the plaque ruptures due to the thin fibrous cap (van der 
Wal et al. 1994) or endothelial erosion (without plaque rupture) exposing the 
underlying collagen, which in turn activates the thromb forming cascade (Farb 
et al. 1996). Plaque rupture is detectable in up to 70% of cases with coronary 
infarction (Falk, Shah, and Fuster 1995). Ruptures occur when the fibrous cap is 
thin and partly destroyed. Activated immune cells are abundant at these sites, 
which produce multiple proteolytic enzymes and inflammatory molecules (van 
der Wal et al. 1994). This transforms the stable plaque into an unstable and 
vulnerable structure that can rupture and induce a thrombus, which in turn 
elicits an acute coronary syndrome (Hansson 2005). Plaques that precipitate 
endothelial erosion are morphologically different, being more fibrous, having an 
intact plaque cap and exhibiting either absent or deeply-seated necrotic cores 
(White, Newby, and Johnson 2016). Interestingly, the plaques in the skin of 
psoriasis and coronary artery both have similarities including the presence of 
proinflammatory cytokines TNF- α, IFN.ɣ, IL-6, IL-17, IL-8, the extravasation 
of white blood cells through the endothelium and Th1, Th17 and regulatory T-
cells (Kivelevitch, Schussler, and Menter 2017).  
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Since atherosclerosis is regarded as a form of chronic vascular inflammation 
(Ross and Glomset 1973), C-reactive protein (CRP), more precisely high-
sensitivity CRP in combination with Framingham risk score (10-year cardio-
vascular risk assessment) has been shown to have a high predictive accuracy 
(Koenig et al. 2004). IL-6, a member of the inflammatory cytokine family 
released from vascular smooth muscle cells, monocytes, macrophages and 
endothelial cells has been shown to have a high impact in atherosclerosis 
(Ridker et al. 2000). Malondialdehyde-modified low-density lipoprotein (MDA-
LDL) is widely used as a marker because its chemical structure is readily-
identifiable and it is the most common aldehyde resulting from lipid peroxi-
dation. Higher levels are associated with fibroatheromas in patients with 
coronary artery disease (Matsuo et al. 2013). Regarding low-molecular com-
pounds, lipidomics has yielded many species including triacylglycerol (TAG) 
54:2, cholesterol ester (CE) 16:1 and phosphatidylethanolamine (PE) 36:5 
(Stegemann et al. 2014). Additionally, machine learning models have been 
applied to discover plasma lipids closely related to coronary artery disease. 
Various phosphatidylcholines, triglycerides, sphingomyelins and other lipids 
were incorporated into statistical models that helped to distinguish cases from 
controls (Meikle et al. 2011). 
 
 
2.5. Concluding remarks  
The application of the various techniques used in metabolomics to discover new 
biomarkers in psoriasis, atopic dermatitis and atherosclerosis is very important 
because it might give new insights into the pathophysiologies of the diseases 
and help to create a premise for new drug targets. Additionally, the application 
of various machine learning methods to create new sample-discriminating 
statistical models could one day prove to be extremely useful in helping doctors 
with the improvement of diagnosis, and consequently lead to better treatment 
for patients.   
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3. AIMS OF THE THESIS 
The primary aim of the current thesis was to analyze the metabolomic profiles 
of patients with plaque psoriasis, atopic dermatitis and atherosclerosis to assess 
the similarities and differences in the discovered metabolites.  
 
The specific aims were the following: 
 
1) Evaluate the serum metabolomic profiles of plaque psoriasis patients using 
targeted and untargeted metabolomic methods and to provide statistical 
models that could be used in the diagnosis and monitoring of treatment. 
2) Discover the metabolites that are characteristic to atopic dermatitis and use 
statistical models that use data from targeted and untargeted metabolomic 
measurements to classify samples. 
3) Analyze the levels of serum phosphatidylcholines and lysophosphatidyl-
cholines and their relations to hemodynamics, endothelial dysfunction and 
arterial stiffness in patients with coronary artery disease and peripheral 
artery disease. 
4) Discover whether there are similarities in metabolite levels in patients with 
plaque psoriasis, atopic dermatitis, and atherosclerosis.   
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4. SUBJECTS AND METHODS 
4.1. Ethics approval 
The permission to perform studies on the metabolomics of skin diseases and 
cardiovascular diseases were granted by the Research Ethics Committee of the 
University of Tartu. The protocols of the Declaration of Helsinki were followed 
and all of the patients and volunteers gave their informed, written consent. Good 
clinical practices were followed when collecting the samples. 
 
 
4.2. Recruitment of volunteers  
For the studies on skin diseases the adult patients with either plaque psoriasis 
or atopic dermatitis were recruited during 2013–2015 at the University Hospital 
of Tartu, the Clinic of Dermatology. The patients were asked to participate 
when they first came in and before the beginning of treatment. The controls 
were age- and sex-matched and asked to participate either from the same clinic 
or from the Clinic of Traumatology and Orthopaedics. It was not counted how 
many volunteers refused to participate; also, the dropout-rate was not calculated 
because subjects only needed to give written consent and samples at the 
beginning of the study. The exclusion criteria for patients and controls included 
comorbid chronic inflammatory skin diseases, diabetes and pregnancy. In total 
the number of patients with plaque psoriasis was 55 (18 women, 37 men, ages 
20–75), 25 with atopic dermatitis (19 women, 6 men, ages 20–55) and 63 
controls (26 women, 37 men, ages 23–75). All of the patients and controls were 
adults to increase the probability that the changes seen in metabolite levels are 
specific to diseases and not due to age. The participants were all Caucasians of 
Eastern European descent (Ottas, Fishman, Okas, Kingo, et al. 2017; Ottas, 
Fishman, Okas, Püssa, et al. 2017). 
For the study on cardiovascular diseases a total of 124 male subjects, 
including 32 patients with PAD, 52 patients with CAD, and 40 clinically 
healthy controls, were enrolled into this study. The patients were recruited from 
the Department of Vascular Surgery and the Department of Cardiology, 
University of Tartu, Estonia. All patients had angiographically proven PAD or 
CAD. The exclusion criteria for both the groups were any comorbid acute or 
chronic inflammatory disease, diabetes mellitus, myocardial infarction, cerebro-
vascular events or revascularization operation during the preceding 6 months, 
unstable angina, cardiac arrhythmias, clinically significant heart failure or 
valvular disease, reduced kidney function (estimated glomerular filtration rate 
<60 ml/min/1.73 m2), presence of cancer, or endocrine pathology. In the PAD 
group, six (16%) patients with CAD as a comorbidity were included in the 
analysis. Age- and gender-matched clinically healthy controls were enrolled 
through local family physicians in the same geographic region. The exclusion 
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criteria included any comorbid acute or chronic inflammatory disease, CAD, 
cerebral or peripheral atherosclerotic disease, diabetes mellitus, cardiac 
arrhythmias, clinically significant heart failure or valvular disease, hypertension, 
reduced kidney function (estimated glomerular filtration rate 
<60 ml/min/1.73 m2), presence of cancer, infectious disease or endocrine 
pathology, or regular use of any medication (Paapstel et al. 2018). 
 
 
4.3. Serum collection protocol 
Blood samples were collected in the morning into 5 ml Vacutainer (REF 
367614) tubes that contain micronized silica particles that help to accelerate the 
clotting process. The blood was left at room temperature for one hour then 
centrifuged at 1300 × g for 20 minutes. The supernatant serum was pipetted into 
300 μl aliquots and stored in the freezer at –80 °C until needed.  
 
 
4.4. Cardiovascular diseases study protocol 
Data on lifestyle factors and medical history were obtained using an interview 
and a self-completed questionnaire. Peripheral venous blood samples were 
collected from all subjects between 8am and 11am after an overnight fast and 
abstinence from tobacco, alcohol, tea, and coffee. Thereafter, height and weight 
were assessed and body mass index was calculated. The subjects were studied 
after 10 min of rest in a supine position in a quiet, temperature- controlled room. 
Brachial blood pressure and carotid-femoral pulse wave velocity (cf-PWV) 
were assessed and pulse wave analysis was conducted. All hemodynamic 
measurements were taken in duplicate and averaged. The study protocol was 
approved by the Ethics Committee of the University of Tartu, and each subject 
gave their written informed consent. 
 
 
4.4.1. Arterial stiffness and central hemodynamic measurements 
The SphygmoCor device (AtCor Medical, Sydney, Australia) was used for non-
invasive assessment of arterial function and hemodynamics. The cf-PWV was 
calculated from the pulse transit time using ECG-gated carotid and femoral 
artery waveform recordings over a known distance (Wilkinson et al. 1998). The 
distance from the suprasternal notch over the umbilicus to the femoral artery 
minus carotid arterial length was used for the calculation of the cf-PWV. In 
addition, aortic augmentation index, corrected for a heart rate (HR) of 75 bpm 
(AIx@75), and central hemodynamic parameters were evaluated. In brief, after 
15 sequential high- quality radial waveforms were recorded at the patient’s left 
wrist using a high-fidelity micromanometer (SPT- 301B; Millar Instruments, 
Houston, Texas), a validated generalized transfer function for calculation of the 
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central aortic pressure waveform was used (Pauca, O’Rourke, and Kon 2001; 
Adji, O’Rourke, and Namasivayam 2011). The augmentation index (%) was 
defined as the ratio of the difference between the second and first systolic peaks 
of the central arterial waveform to the central pulse pressure (Laurent et al. 
2006). 
 
 
4.4.2. Angiographic score 
In patients with PAD, digital subtraction angiography (Axiom Artis; Siemens 
Medical Solutions, Forchheim, Germany) of the aorta and lower extremity 
arteries was performed, using a femoral approach at the Department of Radio-
logy, Tartu University Hospital, Estonia. The Bollinger angiogram scoring 
method takes into account both the severity and location of atherosclerotic 
lesions in the lower extremity arteries (Bollinger et al. 1981). 
 
 
4.4.3. Biochemical analysis 
Venous blood samples were collected in serum separator tubes (BD SST" II 
Advance) and plain tubes (Plain BD Vacutainer Tubes) for clinical biochemical 
and metabolomic analysis, respectively. All samples were centrifuged and the 
supernatant was transferred into 1.5 mL Eppendorf tubes. The tubes were frozen 
at –80°C until assayed. The serum concentrations of interleukin-6, resistin, and 
insulin were determined using The Evidence Investigator (Metabolic Syndrome 
Array-1, Randox Laboratories, Crumlin, UK). The plasma levels of total cho-
lesterol, low- density lipoprotein cholesterol, high-density lipoprotein cholesterol, 
triglycerides, glucose, white blood cell count, platelet count, high-sensitivity  
C-reactive protein, and estimated glomerular filtration rate were measured in a 
local clinical laboratory using automated analyzers following standard labo-
ratory methods (Paapstel et al. 2018). 
 
 
4.5. Measurements using mass spectrometer 
4.5.1. Targeted analysis of metabolites in serum 
Targeted analysis was performed using the AbsoluteIDQTM p180 kit (BIO-
CRATES Life Sciences AG, Innsbruck, Austria). Before the measurements 
began, a 96-well plate report detailing the position of samples, quality controls, 
phosphate buffered saline samples, blank samples and calibration standards was 
generated in the vendor’s software MetIDQTM Carbon 6.0.0. The serum samples 
were thawed on ice, vortexed and centrifuged at 4 °C for 5 minutes at 2750 × g. 
The lyophilized internal standards (IS) were prepared by adding 1200 μl of 
HPLC grade water to the tube, followed by vortexing and shaking for 
27
15 minutes at 1200 rpm. The quality control samples and calibration standards 
were prepared by adding 100 μl of HPLC grade water to the tubes and vortexed, 
followed by shaking for 15 minutes at 1200 rpm. 10 μl of IS was added to all 
wells with the exception of the blank well in position A1 to allow for the 
calculation of the background noise of the mass-spectrometer. 10 μl of serum 
samples and other samples were pipetted according to the generated plate 
report. The samples on the plate were dried using air through evaporator needles 
for 30 minutes. The samples were derivatized in 20 minutes using 50 μl per well 
of a solution containing 31.6% ethanol, water, pyridine and 5% of phenyli-
sothiocyanate. The plate was dried again for 60 minutes after, which the meta-
bolites were extracted using 300 μl per well of 5 mM ammonium acetate 
solution. The measurements consisted of two parts – using flow injection 
analysis (FIA) and liquid chromatography (LC). For the FIA part, 20 μl of each 
sample was transferred to a new 96-well plate where 380 μl of methanol with 
Biocrates Solvent I (one ampule of solvent per 290 μl of methanol) was added. 
The LC part required the transfer of 50 μl of sample to a new 96-well plate and 
dilution with 250 μl of 40% methanol in HPLC grade water. The measurements 
were done on a Sciex 4500 QTRAP mass-spectrometer using an Agilent 1290-
series liquid chromatograph with an Agilent Zorbax Eclipse XDB C18, 3.0 × 
100 mm, 3.5 µm with Pre-Column SecurityGuard, Phenomenex, C18, 4 × 3 mm 
for the LC part. The column temperature was set to 50 °C. The solvent used for 
the FIA part was methanol with Biocrates solvent I; The LC part had two 
solvents – HPLC grade water and acetonitrile with 0.2% of formic acid. The 
targeted analysis used multiple reaction monitoring with predetermined 
retention times and specific mass-to-charge ratios of fragments provided by the 
vendor. The concentrations for the LC part were calculated using Analyst 1.6.2. 
and MetIDQTM Carbon 6.0.0. for the FIA part. As a result, the concentrations of 
20 amino acids, 40 acylcarnitines, 18 biogenic amines, 15 sphingomyelins, 14 
lysophosphatidylcholines, 75 phosphatidylcholines and a sum of hexoses were 
calculated. In addition, the MetIDQTM Carbon provided 44 ratios of various 
metabolites that have biological significance (Ottas, Fishman, Okas, Kingo, et 
al. 2017; Ottas, Fishman, Okas, Püssa, et al. 2017).  
 
 
4.5.2. Untargeted analysis of metabolites in serum 
Untargeted analysis was performed in Papers I and II. For samples in Paper I 
the protocol is as follows. Serum samples were thawed on ice, 100 μl of sample 
was transferred to a new Eppendorf tube and 400 μl of acetonitrile was added. 
The tube was vortexed for 2 minutes and left for 15 minutes at room tempe-
rature to allow for the extraction of metabolites. Then the samples were centri-
fuged for 15 minutes at 15,800 × g at 4 °C. 10 μl of supernatant was used for 
analysis on an ABSciex 3200 QTRAP coupled to a Shimadzu high-performance 
liquid chromatograph (HPLC) using a SeQuant® ZIC®-pHILIC (5 µm poly-
mer) PEEK 150 × 4.6 mm metal-free HPLC column and ZIC®-pHILIC Guard 
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column PEEK 20 × 2.1 m column at room temperature. The parameters for the 
measurement were: solvents used were water and acetonitrile in 0.1% formic 
acid, total runtime was 62 minutes, gradient flow rate was 0.3 ml/min starting 
from 80% acetonitrile to 20% in 32 min, then to 5% in 1 minute where it stayed 
for 8 minutes, followed by rapid gradient to 100% in 5 minutes and back to 
80% for re-equilibration for 8 minutes. The curtain gas of the turbo spray was 
set to 10 au, ion spray voltage to 4500 V, collision gas to “High”, temperature 
to 300 °C, entrance potential to 10 V, declustering potential to 20 V. The 
collision energy was set to 10 V in regular measurements and to either 20 V, 
30 V or 40 V in fragmentation analysis. All of the samples were randomized 
and measured in negative and positive modes from 50 to 1500 mass-to-charge 
ratios (m/z). The injection volume was 10 μl. Enhanced Product Ion mode was 
used for fragmentation analysis using respective values and the same column 
(Ottas, Fishman, Okas, Kingo, et al. 2017).  
In Paper II the samples were prepared according to a protocol by Want et al 
(Want et al. 2010) and is as follows. The serum samples were left to thaw on 
ice, 20 μl of each sample was pipetted to a separate tube to make a pooled 
sample for quality control analysis. Per 50 μl of sample, 150 μl of ice cold 
methanol was added to precipitate proteins and solve metabolites. The samples 
were vortexed for 30 seconds and left for 20 minutes at –20 °C after, which they 
were centrifuged at 4 °C for 15 minutes at 16089 × g. 150 μl of supernatant was 
transferred to a new tube and lyophilized using a SpeedVac lyophilizer. 100 μl 
of HPLC grade water was added to the freeze-dried samples, vortexed for 30 
seconds, centrifuged at 4 °C for 15 minutes at 16089 × g. 90 μl of supernatant 
was transferred to a glass vial for measurements on a 6450 UHD Accurate Mass 
Q-TOF tandem liquid chromatograph with 100 series quaternary pump 
(Agilent, USA) using an EclipsePlus C18 RHD 1.8 μm 2.1 × 50 mm column 
(Agilent, USA) at 40 °C. The samples were measured according to a slightly 
modified protocol by Want et al (Want et al. 2010, 2012). The solvents used 
were methanol and water in 0.1% formic acid, total runtime was 26 minutes, 
gradient flow rate was 0.3 ml/min starting from 99.9% water for 2 minutes, 
going to 75% in 4 minutes, then to 20% in 4 minutes, to 10% in 2 minutes and 
gradually to 0.1% in 9 minutes where it stayed for 2 minutes, ramping back up 
in 1 minute to 99.9% for the last 2 minutes. Capillary voltage was set to 3.2 kV 
for ESI+ and 2.4 kV for ESI-, source temperature was 120 °C, desolvation 
temperature 350 °C, cone gas glow 25 litres/hour, desolvation gas glow 900 
litres/h. The injection volume was 5 μl. The collision energy was at 10 V for 
ESI measurements; 20 V and 40 V for fragmentation analysis (Ottas, Fishman, 
Okas, Püssa, et al. 2017).  
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4.5.3. Identification of metabolites 
The fragmentation spectra and individual mass-to-charge ratios of peaks from 
untargeted analysis were compared visually and numerically to spectra from 
multiple public databases e.g. HMDB (Wishart et al. 2017), MassBank (Horai et 
al. 2010), METLIN (Smith et al. 2005) and LipidMaps (Fahy et al. 2007). A 
compound from fragmentation analysis was considered identified when the 
spectra with its m/z peaks and relative heights were identical to spectrums from 
online databases.  
 
 
4.6. Processing and statistical analysis of data 
4.6.1. The pre-processing and analysis of untargeted data  
in the study of skin diseases 
The data from Papers I and II were processed similarly where the acquired 
vendor files (.wiff for QTRAP 3200, .d for Agilent 6450 UHD) were first 
converted to .mzXML using the MSConvert software (Chambers et al. 2012). 
RStudio version 0.98.501 (R Development Core Team 2010) was used to 
extract the peaks with XCMS (Smith et al. 2006) and processed further using 
mzMatch.R (Scheltema et al. 2011) that allowed the combination of biological 
replicates, retention time correction, QC correction, Reproducibility Standard 
deviation filtering, blank filtering with gap filling, filtering the minimum 
number of detections (at least six) and the matching of related peaks. In Paper I 
the data was analyzed using Mann-Whitney-Wilcoxon (MWW) test. In Paper II 
the data was processed further – log10 transformed, mean subtracted and divided 
by standard deviation, then tested for normality using a Shapiro-test after, which 
the Mann-Whitney-Wilcoxon test was applied. All of the values from the 
statistical test were FDR 5% corrected (Ottas, Fishman, Okas, Kingo, et al. 
2017; Ottas, Fishman, Okas, Püssa, et al. 2017). 
 
 
4.6.2. The pre-processing and analysis of targeted data 
In Paper I the metabolites that had zero variance were removed. Scaling and 
centering was applied to all the metabolite values in the dataset. In Paper II the 
data were log10 transformed and normalized through the subtraction of mean 
and the division of the standard deviation. In Paper III the data were processed 
even more thoroughly – to avoid unwanted bias the metabolites, which limits of 
detection and the lower limits of quantitation were lower than given in the 
vendor’s specifications were discarded. Using the ‘boxplot’ function in R the 
metabolites with concentration values smaller or larger than 1.5 × interquartile 
range were considered as outliers and removed. Using the ‘mice’ package, the 
now missing values were imputed based on corresponding metabolite values 
from other samples. A batch effect was discovered that was independent of 
measurement time, gender, phenotype or the time of sample collection. To 
correct for the batch effect, the samples were normalized within either batch 
that resulted in comparable groups. In Paper I, MWW test was used, in Paper II 
the non-paired t-test was used and in Paper III the non-parametric Kruskal-
Wallis rank-sum test and Wilcoxon rank-sum tests were applied for the dis-
covery of metabolites that differentiate the phenotype (Ottas, Fishman, Okas, 
Püssa, et al. 2017; Ottas, Fishman, Okas, Kingo, et al. 2017; Paapstel et al. 
2018). 
 
 
4.6.3. Machine learning and statistical modeling for the discovery and 
validation of metabolites 
Using classical statistical tests is vital and important to discovering phenotype 
differentiating metabolites. Machine learning and statistical modeling provide 
the added benefit of cross-validating the results while providing predictive 
models that can be used for the phenotypic classification of new samples. In 
Paper I, to discriminate between psoriasis patients and controls the random 
forest algorithm (Tin Kam Ho and Ho, n.d.) was applied, which uses a variety 
of decision trees that are built using random subsets from the original data. 
Three feature selection methods were used in parallel to cross-check and select 
only relevant metabolite features – a recursive feature elimination method, a 
genetic algorithm (Mitchell 1998) and a filter method (Saeys, Inza, and 
Larranaga 2007). Fivefold cross-validation strategy was applied due to the lack 
of training data as suggested by Ambroise et al. (Ambroise and McLachlan 
2002). In Paper II three widely used algorithms were applied for machine 
learning and to verify the statistical importance of the metabolites found using 
univariate tests: GLMNET (Friedman, Hastie, and Tibshirani 2010), PDA 
(Hastie, Buja, and Tibshirani 1995) and RandomForest (Liaw and Wiener 
2002). These methods were used for targeted and untargeted data. Using the 
results from univariate tests as features for a supervised model can lead to the 
inflation of accuracy for the constructed classifiers; this is called selection bias 
(Cawley and Talbot 2010). The three classifiers used the whole dataset using a 
5-fold cross-validation algorithm (Geisser 1993) for training to avoid selection 
bias. This was repeated 5 times to validate the metabolites and to avoid over-
fitting, which is when a model is unable to generalize to unavailable data 
because of the limited sample size of a training set (Ng, n.d.). In Paper III the 
machine-learning algorithms used were GLMNET (Friedman, Hastie, and 
Tibshirani 2010), RandomForest (Liaw and Wiener 2002) and support vector 
machines (“Support Vector Machines” 2009). The training of algorithms was 
done without specific feature selection although 5-fold cross validation repeated 
5 times was still applied (Ottas, Fishman, Okas, Kingo, et al. 2017; Ottas, 
Fishman, Okas, Püssa, et al. 2017). 
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4.6.4. Principal component analysis 
Metabolomics analysis yields large amounts of data – over 200 data points 
when measuring the concentrations of known compounds using targeted meta-
bolomics and thousands of data points when measuring all of the charged ions 
in a run using untargeted metabolomics methods. Using univariate statistical 
methods usually provides a handful of metabolites that differ statistically 
significantly between samples and gives a rough idea of variability in samples. 
Principal component analysis (PCA) however can be used to reduce the 
dimensionality of large datasets, which can help with the interpretability while 
minimizing the loss of information. This is achieved by the creation of new 
uncorrelated variables called principal components (Jolliffe and Cadima 2016), 
which can either be used for data visualization or the discovery of relevant 
biomarkers. The visualization of data using PCA was used in Papers I–II but not 
for feature selection (Ottas, Fishman, Okas, Püssa, et al. 2017; Ottas, Fishman, 
Okas, Kingo, et al. 2017). 
 
 
4.6.5. Statistical analysis in cardiovascular study 
In Paper III, the SPSS software for Windows, version 22.0 (SPSS, Chicago, IL, 
USA), was used for the statistical analyses. One-way analysis of variance was 
employed or a Kruskal Wallis test was conducted to determine differences 
between the mean or median values of continuous variables among the groups. 
The normality of the distribution of variables was assessed using the Shapiro 
Wilk test. The serum concentrations of glycerophospholipids were logarithmi-
cally transformed as they were positively skewed. Analysis of covariance was 
employed to adjust cf-PWV levels for mean arterial pressure and glycero-
phospholipid levels for BMI, current smoking status, and statin therapy. For 
comparing dichotomous measures, the Fisher-Freeman-Halton test was 
employed. Univariate correlations were reported as the Spearman rank 
correlation coefficient (rho). The Benjamini Hochberg procedure was used to 
control the false discovery rate at the level of 0.05 [18]. Multivariate analysis 
was performed using a stepwise (forward, followed by backward) multiple 
linear regression. The independent variables entered into the models were 
chosen on the basis of their biological relevance and/ or statistical significance 
from univariate analyses (lysoPC a C17:0, lysoPC a C18:0, lysoPC a C20:4, 
mean age, BMI, mean arterial pressure, interleukin-6, total cholesterol, low-
density lipoprotein cholesterol, glucose, resistin, platelet count, antihypertensive 
treatment, and statin use). All statistical tests were checked for violations of 
assumptions (Paapstel et al. 2018). 
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5. RESULTS 
5.1. The metabolomic profile of plaque psoriasis  
In Paper I where plaque psoriasis patients’ serum metabolites were compared to 
controls the statistically significant differences for targeted analysis are given in 
Table 1. The levels of acylcarnitines, mainly nonaylcarnitine (C9), dodecanoyl-
carnitine (C12), decadienylcarnitine (C10.2), and pimelylcarnitine (C7.DC) had 
all lower concentrations in psoriasis patients’ serums. Phosphatidylcholine 
diacyls (PC aa) C36:5/C36:6 and phosphatidylcholine acyl-alkyls (PC ae) 
C38:0/C40.6 were all higher levels of concentration in controls’ serum. Gluta-
mate (Glu), ornithine (Orn), phenylalanine (Phe), and methioninesulfoxide 
(Met.SO) concentrations were higher in psoriasis subjects. Ratios of acyl-
carnitine to free carnitine (C2...C0), short-chain acylcarnitines to free carnitine 
(X.C2.C3...C0), citrulline to ornithine (Cit... Orn), esterifed carnitine to free 
carnitine (Total.AC...C0), putrescine to ornithine (Putrescine...Orn), and long-
chain acyl-carnitines to free carnitine ([C16 + C18]/C0) were all statistically 
significantly higher in controls, whereas the levels of the fraction of 
sulfoxidized methionine of the unmodified methionine pool (Met.SO...Met) 
were higher in psoriasis patients. 
 
Table 1. Statistically significantly different metabolites and their ratios from targeted 
analysis of serum. 
Metabolite 
abbreviation 
Metabolite p-value Psoriasis mean 
μM ± SD 
Control mean 
μM ± SD 
Met.SO Methionine- sulfoxide 6.06E-06 0.88±0.37 0.51±0.27 
Met.SO...Met Fraction of sulfoxidized 
methionine of the 
unmodified methionine 
pool 
2.65E-05 0.04±0.02 0.02±0.01 
C9 Nonaylcarnitine 0.002 0.04±0.01 0.05±0.01 
Glu Glutamate 0.002 92.85±66.43 49.06±22.76 
Cit...Orn Ratio of citrulline to 
ornithine 
0.002 0.37±0.13 0.44±0.12 
C2...C0 ratio of acetylcarnitine 
to free carnitine 
0.004 0.17±0.08 0.22±0.08 
X.C2.C3....C0 Ratio of short chain 
acylcarnitines to free 
carnitine 
0.005 0.18±0.08 0.23±0.08 
PC.aa.C36.6 Phosphatidylcholine 
diacyl C36:6 
0.006 0.68±0.27 0.89±0.33 
Total.AC...C0 Ratio of esterified to 
free carnitine 
0.006 0.25±0.1 0.31±0.1 
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The results for untargeted analysis in Paper I are given in Table 2. Out of 22 
metabolites, 12 could be identified. Urea, taurine, phytol, 1,11-undecanedi-
carboxylic acid, glycerophosphocholines PC(16:0/18:2), PC(18:1/0:0), 
PC(16:0/18:1), PC(16:0/0:0), PC(20:4/0:0), PC(18:1/0:0), and phosphati-
dylethanolamine PE(20:4/0:0) were all higher in psoriasis patients serum. 
 
Table 2. Statistically significantly different m/z-s from untargeted analysis of serum 
Negative 
ionization 
Mass-to-
charge ratio 
p-value Intensity levels higher 
in psoriasis or controls?
Metabolite 
  189 2.80E-07 Psoriasis No match in databases 
  802.5 8.28E-05 Psoriasis PC(16:0/18:2) + FA 
  556.32 2.91E-04 Psoriasis PC(18:1/0:0) 
  129.17 4.82E-05 Psoriasis No match in databases 
  249 1.46E-04 Psoriasis No match in databases 
  198 8.36E-05 Psoriasis No match in databases 
  325.5 1.03E-04 Psoriasis No match in databases 
  249 1.30E-04 Psoriasis No match in databases 
  243.12 9.73E-08 Psoriasis 1,11-Undecanedi-
carboxylic acid 
     
Metabolite 
abbreviation 
Metabolite p-value Psoriasis mean 
μM ± SD 
Control mean 
μM ± SD 
PC.ae.C38.0 Phosphatidylcholine 
acyl-alkyl C38:0 
0.007 1.73±0.5 2.17±0.69 
C7.DC Pimelylcarnitine 0.011 0.019±0.006 0.024±0.008 
Orn Ornithine 0.011 99.79±29.44 82.28±20.85 
PC.ae.C40.6 Phosphatidylcholine 
acyl-alkyl C40:6 
0.011 3.39±0.99 4.02±1.01 
Putrescine...Orn Ratio of putrescine to 
ornithine 
0.013 0.001±0.001 0.002±0.001 
PC.aa.C36.5 Phosphatidylcholine 
diacyl C36:5 
0.019 24.78±13.25 34.34±19.98 
Phe Phenylalanine 0.026 82.91±18.96 72.46±13.51 
[C16+C18]/C0 Ratio of long chain 
acylcarnitines to free 
carnitine 
0.027 0.004±0.001 0.005±0.001 
C12 Dodecanoylcarnitine 0.036 0.1±0.036 0.124±0.051 
C10.2 Decadienylcarnitine 0.044 0.069±0.021 0.076±0.02 
  
  
The PCA plot from targeted analysis is based on the summed concentrations of 
similar metabolite classes (Figure 1). The overlapping group clustering of 
controls and psoriasis samples is best observed along principal component 1 
that accounts for 35% of variability. Biogenic amines, glycerophospholipids, 
and metabolite ratios are responsible for the clustering. The PCA plot based on 
the data from positive and negative untargeted analysis data displays very clear 
clustering of the groups on the axis of PC1 that accounts for 55% of variability 
(Figure 2). 
With recursive feature elimination in Paper I, the random forest model 
achieved 0.86 AUC, 0.77 sensitivity and 0.74 specificity averaged across five 
repetitions. 15 metabolites were selected into a final model using this method. 
Feature selection using internal importance measures that applied inside random 
forest model yielded 46 metabolites and 0.85 AUC resampling performance 
with sensitivity and specificity 0.77 and 0.74 correspondingly. Finally, the best 
model that used genetic algorithm for feature selection kept 90 features and 
achieved 0.85 AUC. 9 metabolites/ratios was selected by all three methods and 
these are Met.SO, Cit...Orn, Met.SO...Met, X.C2.C3...C0, C2...C0, C9, Orn, 
C7.DC, and PC.aa.C38.5. Figure 3 shows the difference in concentrations of 
nine overlapping metabolites between healthy subjects and psoriasis patients. 
All of these differences are statistically significant with the exception of 
PC.aa.C38.5, whereas the maximum Wilcoxon test p-value equals 0.011 for Orn 
and the minimal 6.06E−06 for Met.SO (Ottas, Fishman, Okas, Kingo, et al. 
2017).  
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Positive 
ionization 
Mass-to-
charge ratio 
p-value Intensity levels higher 
in psoriasis or controls?
Metabolite 
  760.56 7.91E-07 Psoriasis PC(16:0/18:1) 
  496.38 8.15E-07 Psoriasis PC(16:0/0:0) 
  159 3.07E-06 Psoriasis No match in databases 
  126 1.59E-03 Psoriasis Taurine 
  544.38 1.31E-06 Psoriasis PC(20:4/0:0) 
  282 1.58E-06 Psoriasis No match in databases 
  297 1.10E-05 Psoriasis No match in databases 
  297.059 4.30E-03 Psoriasis Phytol 
  522.36 2.79E-03 Psoriasis PC(18:1/0:0) 
  120 3.94E-06 Psoriasis No match in databases 
  502.38 0.0108 Psoriasis PE(20:4/0:0) 
  679.5 5.54E-08 Psoriasis No match in databases 
  60.69 1.23E-05 Psoriasis Urea 
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Figure 1. PCA plot of the targeted analysis. Psoriasis samples are marked as gray 
triangles and control samples as black circles. The metabolite groups responsible for the 
separation are marked at the end of the arrows. X and Y axes represent the percentage 
of variability explained by principal components one and two 
 
 
Figure 2. PCA plot of the untargeted analysis. Controls are shown as gray triangles, 
while psoriasis patients are marked as black circles. The metabolites responsible for the 
separation are shown at the end of the arrows. X and Y axes represent the percentage of 
variability explained by principal components one and two 
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Figure 3. Distribution of standardized signals for nine metabolites overlapping in all 
three modeling methods. Red dots represent standardized concentrations for psoriasis 
patients, while blue ones represent controls. 
 
 
5.2. The metabolomic profile of atopic dermatitis  
In Paper II atopic dermatitis patient serum metabolites were compared to 
controls using both targeted and untargeted methods. The targeted analysis 
yielded a total of 7 metabolites that differ statistically significantly between 
groups: acetylcarnitine (C2), phosphatidylcholine diacyl C38:5 (PC.aa.C38.5), 
phosphatidylcholine diacyl C40:5 (PC. aa.C40.5), ratio of short chain 
acylcarnitines (acylcarnitine–C2, propionylcarnitine–C3) to free carnitine (C0), 
ratio of acetylcarnitine to free carnitine (C2. . .C0), fraction of dicarboxylic 
acylcarnitines of the total acylcarnitines (Total.AC.DC. . .Total.AC) and ratio of 
esterified acylcarnitines to free carnitine (Total.AC. . .C0). The untargeted 
analysis resulted in 6 statistically differing metabolites out of which 3 were 
identified: a peptide DSGEGDFXAEGGGVR and phosphatidylcholine PC(16:0– 
16:1) /(14:0–18:1) levels in the serum were both significantly higher in AD 
patients while phosphatidylcholine PC(16:1/20:4) was significantly lower in 
AD patients’ serum. No statistically significant changes could be seen in amino 
acids, biogenic amines, hexoses or sphingolipids in targeted analysis. The 
results from targeted analysis are shown in Table 3 while untargeted results are 
given in Table 4. 
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Table 3. Targeted analysis results from non-paired t-test where atopic dermatitis 
patients’ serum metabolites were compared to controls  
  
Table 4. Untargeted analysis results from Mann-Whitney Wilcoxon test where atopic 
dermatitis patients’ serum metabolites were compared to controls 
  
PCA plots constructed on the whole data from targeted (Figure 4) and untargeted 
analysis (Figure 5) did not show any hidden batch effects that could bias 
metabolite identification. The separate clustering of phenotypic groups could 
also not be seen, suggesting that the use of simple linear models will not 
differentiate classes. PCA plots generated using only statistically significantly 
different metabolites produced visually distinct clusters of samples that 
correspond to studied phenotypic groups (Figures 6 and 7). 
Metabolite p-value AD mean Control mean 
C2 0.026 –0.617 0.397 
PC.aa.C38.5 0.026 –0.667 0.142 
PC.aa.C40.5 0.026 –0.663 0.195 
X.C2.C3....C0 0.026 –0.232 0.737 
C2...C0 0.026 –0.237 0.736 
Total.AC.DC...Total.AC 0.026 0.551 –0.353 
Total.AC...C0 0.036 –0.174 0.698 
Positive mode  m/z Identification 
AD 
mean
Control 
mean 
p-value 
  545.393 unknown –0.98 0.85 0.0075 
  737.735 DSGEGDFXAEGGGVR 0.98 –0.85 0.0075 
  780.611 PC(16:1/20:4) –0.91 0.79 0.0192 
  829.891 unknown –0.91 0.79 0.0192 
  641.512 unknown –0.77 0.67 0.0430 
 Negative mode 537.507 PC(16:0–16:1) /(14:0–18:1) 0.84 –0.73 0.0351 
 
Figure 4. PCA plot for targeted analysis based on the whole data. Red circles—cases; 
blue squares – controls. Initially, both groups largely overlap, also PCs explain a modest 
amount of variance. 
 
Figure 5. PCA plot for untargeted analysis based on negative (A), positive (B) and a 
combination of both (C) datasets. Red circles – cases, blue squares – controls. It can be 
seen that adding the dataset obtained from negative mode does not explain additional 
variance in the positive mode dataset, on the contrary – the amount of variance 
explained by the first and second principle components decreases for the combined 
dataset, which suggests that there is very little important information in the dataset 
obtained from negative mode. 
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Figure 6. PCA plot for targeted analysis based on the significantly different meta-
bolites. Red circles – cases; blue squares – controls. The groups are visually separable, 
although there is still a significant overlap between samples. It is important to note that 
PCs explain much more variance than in Fig 1. 
 
 
Figure 7. PCA plots based only on metabolites that were found to be significant in 
untargeted analysis for positive (A) and combined (B) datasets. Red circles – cases; blue 
squares – controls. Points on both plots are visually separable and form very clear 
clusters that correlate with phenotypes. 
 
 
 
 
In targeted analysis, machine-learning models achieved an average performance 
close to 75%, suggesting that it is possible to differentiate between cases and 
controls using metabolites measured in targeted analysis (Figure 8A). 
Importantly, metabolites identified as significant in targeted analysis appear in 
the top of the list of metabolites that were most influential for Random Forest 
classifier (Figure 8B). 
 
Figure 8. (A) Average classification performance (accuracy) of three distinct classifiers 
(rf = RandomForest, pda = Penalised Discriminant Analysis and glmnet = Lasso and 
Elastic-Net Regularized Generalized Linear Model) on data from targeted analysis. The 
performance was measured with cross-validation algorithm over 5 folds and 5 
repetitions. Average performance reaches 70%–75%,, which suggests that metabolites 
are indeed capable of distinguishing between cases and controls. (B) Top 20 most 
important metabolites used by RandomForest classifier. Metabolites identified as 
significantly different in targeted analysis are highlighted. We can see that indeed 
almost all metabolites (except for C2. . .C0) identified as significantly different are in 
the top of the list. 
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For untargeted analysis all three machine-learning models show high accuracy 
(~90%) on all three modes (negative, positive and combined) (Figure 9). 
Metabolites that were identified using statistical tests in untargeted analysis 
were ranked first by the RandomForest algorithm in all three modes (Fig 10), 
suggesting that these metabolites carry true discriminative power between 
classes. Also, the constructed PCA plot based on significant metabolites clearly 
shows the separation between classes of samples (Fig 7) (Ottas, Fishman, Okas, 
Püssa, et al. 2017). 
  
 
Figure 9. Averaged classification performance (accuracy) of three classifiers (rf = 
Random Forest, pda = Penalized Discriminant Analysis and glmnet = Lasso and Elastic-
Net Regularized Generalized Linear Model) on data from untargeted analysis. Their 
performance was measured with cross-validation algorithm over 5 folds and 5 repetitions 
on data obtained with negative mode (A), positive mode (B) and a combination of two 
modes (C). We can see that on average all three classifiers show high accuracy (for all 
about 90% on average). Hence, it is possible to conclude that metabolites in untargeted 
analysis indeed have a discriminative power. 
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Figure 10. Top 20 of the most influential metabolites used by the RandomForest 
algorithm trained on data obtained from negative mode (A), positive mode (B) and a 
combination of two modes (C). Metabolites identified as significantly different from 
untargeted analysis (highlighted) are at the top of the list that was used by Random 
Forest classifier to obtain highly accurate classification performance. 
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5.3. The inverse relations of serum phosphatidylcholines 
with cardiovascular diseases 
5.3.1. Baseline characteristics of the study population 
The hemodynamic and biochemical characteristics of patients with PAD, CAD 
and controls are summarized in Table 5. 
The values are presented as means ± standard deviation, medians (inter-
quartile range), or prevalence (%). PAD, peripheral arterial disease; CAD, 
coronary artery disease; BMI, body mass index; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; MAP, mean arterial pressure; AIx@75, augmen-
tation index adjusted to a heart rate of 75 beats per minute; cf-PWV, carotid–
femoral pulse wave velocity; ADMA, asymmetric dimethylarginine; WBC, 
white blood cell count; HDL, high-density lipoprotein; LDL, low-density lipo-
protein; hsCRP, high-sensitivity C-reactive protein; eGFR, estimated glomerular 
filtration rate; ND, not detectable. 
There were no significant differences in mean age, peripheral diastolic or 
central diastolic blood pressure, estimated glomerular filtration rate, ADMA, 
ADMA/arginine, total cholesterol, low-density lipoprotein cholesterol, glucose, 
insulin levels, or platelet count. The patients with PAD differed statistically 
significantly from both patients with CAD and the control subjects in relation to 
central systolic blood pressure, AIx@75, cf-PWV, arginine, triglycerides, white 
blood cell count, high-sensitivity C-reactive protein, interleukin-6, prevalence 
of current smoking, antihypertensive therapy, and statin use. Differences in the 
levels of peripheral systolic blood pressure, mean arterial pressure, HR, high-
density lipoprotein cholesterol, and the proportions of antiplatelet therapy only 
emerged from comparisons with the controls. Higher BMI values were observed 
in the CAD group than in the PAD group. The CAD group also had significantly 
increased cf-PWV, HR, and white blood cell count and higher prevalence of 
antihypertensive, antiplatelet, and statin therapy compared to the controls. After 
adjusting for multiple comparisons, BMI, current smoking status and statin 
therapy, the PAD group had significantly lower serum levels of PC aa C28:1, 
PC aa C30:0, PC aa C32:2, PC ae C30:0, and PC ae C34:2 compared to the 
healthy controls (Fig. 1). In addition, patients with CAD had lower serum levels 
of PC aa C32:2 and lysoPC a C18:2 compared to the controls (Fig. 1). The ratio 
between total lysoPC and total PC (expressed as a percentage) was 18.1 3.5, 
19.3 3.5, and 21.4 3.3 for patients with PAD, patients with CAD, and healthy 
controls, respectively (p < 0.001). 
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Table 5. Baseline characteristics of the study participants. 
Variable PAD patients CAD patients Healthy controls p-value 
(n=32) (n=52) (n=40) 
Age (years) 61.7 ± 9.0 63.2 ± 9.2 60.3 ± 7.1 0.27 
BMI (kg/m2) 25.8 ± 3b 27.9 ± 3.5 26 ± 3.4 0.02 
Peripheral SBP (mmHg) 142.5 ± 17.7a 135 ± 14.5 129.5 ± 15.0 0.003 
Peripheral DBP (mmHg) 79.7 ± 7.5 78.5 ± 8.0 77.8 ± 7.3 0.59 
Central SBP (mmHg) 132.7 ± 16.5a,b 122.7 ± 11.1 119.3 ± 13.9 <0.001 
Central DBP (mmHg) 80.7 ± 7.8 79.7 ± 7.6 78.6 ± 7.3 0.51 
MAP (mmHg) 102.5 (95–107.5)a 96.0 (91.6–101.4) 92.5 (89.0–100.0) 0.01 
Heart rate (bpm) 65.5 (57.5–74.5)a 62 (58–68)a 57.3 (53–62.5) 0.001 
AIx@75 (%) 28 ± 7.4a,b 18.9 ± 7.2 15.3 ± 8.0 <0.001 
cf-PWV (m/s)c 10.5 ± 2.9a,b 9.7 ± 2.6a 8.2 ± 1.7 0.007 
ADMA (μM) 0.46 (0.42–0.57) 0.43 (0.35–0.52) 0.44 (0.37–0.49) 0.07 
Arginine (μM) 122.7 ± 22.7a,b 102.4 ± 21 99.4 ± 22.3 <0.001 
ADMA/arginine 0.004 (0.003–0.005) 0.004 (0.003–0.005) 0.005 (0.003–0.005) 0.36 
Total cholesterol (mmol/l) 5.3 ± 1.1 5.1 ± 1.0 5.5 ± 0.9 0.43 
HDL-cholesterol (mmol/l) 1.3 ± 0.4a 1.5 ± 0.4 1.6 ± 0.4 0.003 
LDL-cholesterol (mmol/l) 3.4 (2.7–4.2) 3.2 (2.8–4.1) 3.6 (3.3–4.2) 0.19 
Triglycerides (mmol/l) 1.6 (1.4–2.1)a,b 1.2 (0.8–1.6) 1.0 (0.7–1.5) 0.002 
Glucose (mmol/l) 5.5 (5.2–5.9) 5.8 (5.3–6.3) 5.8 (5.4–6.1) 0.07 
Insulin (uIU/mL) 4.9 (3.1–8.2) 5.8 (4.4–8.8) 4.9 (3.3–7.5) 0.13 
WBC count (x109/L) 8.2 (6.3–9.1)a,b 6.4 (5.2–7.9)a 5.1 (4.7–5.8) <0.001 
Platelet count (x109/L) 240 (192–298) 213 (182–247) 210 (186–239) 0.18 
hs-CRP (mg/l) 3.2 (1.1–6.8)a,b 1.3 (0.7–2.8) 1.2 (0.7–2.1) <0.001 
Interleukin-6 (pg/mL) 2.81 (1.14–5.57)a,b 1.33 (0.74–1.98) 0.95 (0.64–1.29) <0.001 
Resistin (ng/mL) 3.5 (2.6–4.4) 3.4 (2.6–4.5) 2.8 (2.3–3.7) 0.18 
eGFR (ml/min/1,73m2) 94 (78–100) 85 (73–97) 89 (79–93) 0.24 
Angiographic score (AU) 27.8 ± 7.1 ND ND ND 
Current smoking, n (%) 25 (78)a,b 13 (25) 5 (13) <0.001 
Medication, n (%)     
 Antihypertensive therapy 19 (59)a,b 48 (92)a 0 (0) <0.001 
 Antiplatelet therapy 13 (41)a 34 (65)a 0 (0) <0.001 
 Statin therapy 7 (22)a,b 28 (54)a 0 (0) <0.001 
a = <0.05 vs control group 
b = <0.05 vs CAD group 
c = cf-PWV has been adjusted for MAP 
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Figure 11. Bar chart showing the median concentrations of selected phosphatidyl-
choline (PC) and lysophosphatidylcholine (lysoPC) species across the three study 
groups. *p-values were adjusted for body mass index, current smoking status, and statin 
use. The Benjamini–Hochberg procedure was used to account for multiple testings. A 
corrected p-value <0.05 was considered to be statistically significant. 
Abbreviations: PAD, peripheral arterial disease; CAD, coronary artery disease. 
 
 
5.3.2. Relationships of arterial stiffness, endothelial dysfunction 
biomarkers, and resting heart rate with glycerophospholipids 
Table 6 presents the correlation coefficients of lysoPC a C16:0, lysoPC a C17:0, 
lysoPC a C18:0, lysoPC a C20:4, and PC aa C32:2 for the three study groups.  
 
Table 6. Coefficients of Spearman’s rank correlation between clinical characteristics 
and selected glycerophospholipids for the three study groups. 
  lysoPC a 
C16:0 
lysoPC a 
C17:0 
lysoPC a 
C18:0 
lysoPC a 
C20:4 
PC aa 
C32:2 
PAD patients (N=32)      
cf-PWV –0.57* –0.16 –0.45* –0.28 –0.6** 
Heart rate –0.34 –0.56** –0.45* –0.3 –0.47* 
Angiographic score –0.34 ––0.05 –0.2 –0.41* 0.01 
ADMA –0.49* –0.24 –0.44* –0.5* –0.42* 
ADMA/Arginine –0.47* –0.15 –0.38* –0.44* –0.21 
Total cholesterol 0.54* 0.09 0.58* 0.16 0.66** 
LDL-cholesterol 0.45 –0.01 0.47* 0.07 0.56** 
HDL-cholesterol 0.29 0.13 0.47* 0.07 0.32 
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 Abbreviations: PAD, peripheral arterial disease; CAD, coronary artery disease; PC, phosphatidyl-
choline; lysoPC, lysophosphatidylcholine; a, acyl; aa, diacyl; ae, acyl-alkyl; cf-PWV, carotid-
femoral pulse wave velocity; ADMA, asymmetric dimethylarginine; LDL, low-density lipoprotein; 
HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein. Statistically significant 
correlation coefficients are presented in bold. * Benjamini-Hochberg adjusted p-value <0.05, 
** Benjamini-Hochberg adjusted p-value <0.01. 
 
  
  lysoPC a 
C16:0 
lysoPC a 
C17:0 
lysoPC a 
C18:0 
lysoPC a 
C20:4 
PC aa 
C32:2 
Interleukin-6 –0.54* –0.65** –0.6** –0.49* –0.44* 
hs-CRP –0.42* –0.54** –0.42* –0.18 –0.38 
Insulin –0.38 –0.22 –0.42* –0.38 –0.31 
CAD patients (N=52)      
cf-PWV –0.08 –0.04 –0.11 –0.36* –0.04 
Heart rate –0.07 –0.18 –0.12 –0.26 –0.13 
ADMA –0.32* –0.04 –0.26 –0.15 0.01 
ADMA/Arginine –0.28 –0.08 –0.22 –0.1 0.03 
Total cholesterol 0.56** 0.16 0.55** 0.22 0.37 
LDL-cholesterol 0.47** 0.11 0.55** 0.24 0.27 
HDL-cholesterol 0.11 0.12 –0.04 –0.12 0.27 
Interleukin-6 –0.14 –0.36* –0.31* –0.19 –0.21 
hs-CRP –0.09 –0.21 –0.11 0.05 –0.06 
Insulin –0.07 –0.1 –0.06 –0.24 0.17 
Healthy controls (N=40)      
cf-PWV 0.18 0.1 0.1 –0.06 0.05 
Heart rate –0.01 –0.27 –0.13 0.05 0.23 
ADMA –0.18 –0.2 –0.2 –0.09 –0.15 
ADMA/Arginine –0.21 –0.18 –0.2 –0.08 –0.13 
Total cholesterol 0.25 0.22 0.31 0.27 0.13 
LDL-cholesterol 0.13 0.13 0.26 0.12 0.1 
HDL-cholesterol 0.21 0.34 0.29 0.4* 0.1 
Interleukin-6 0.02 –0.26 –0.2 0.01 –0.19 
hs-CRP –0.19 –0.33 –0.17 0.07 –0.01 
Insulin –0.24 –0.43* –0.38* –0.37* 0.09 
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After adjustment for multiple testing, cf-PWV showed negative correlation with 
serum levels of PC aa C32:2, lysoPC a C16:0, and lysoPC a C18:0 for patients 
with PAD. The lysoPC a C20:4 exhibited inverse correlation with cf-PWV for 
the CAD group, while no significant relationships were observed between 
arterial stiffness and individual lipid species for the controls. In multiple 
regression analysis, however, the above mentioned lipids lost their significant 
relationships with cf-PWV for both the patient groups (data not shown). Resting 
HR correlated negatively with lysoPC a C17:0, lysoPC a C18:0, and PC aa 
C32:2 for patients with PAD but not for patients with CAD or controls (Table 6). 
After adjusting for potential confounders, lysoPC a C17:0 retained significance 
as a determinant of HR for the PAD group (Table 7). The lysoPC a C20:4, 
lysoPC a C16:0, and lysoPC a C18:0 were inversely related to ADMA/arginine 
only for patients with PAD. The ADMA correlated negatively with lysoPC a 
C20:4, lysoPC a C18:0 and PC aa C32:2 for the PAD group, while lysoPC a 
C16:0 showed inverse relationship with ADMA for both patients with PAD and 
CAD (Table 6). However, multiple regression analysis revealed that after 
adjusting for potential confounders, only lysoPC a C20:4 remained a significant 
determinant of both ADMA/arginine and ADMA for the PAD group, while 
lysoPC a C18:0 played a similar role for the patients with CAD (Table 8). 
Finally, lysoPC a C20:4 correlated inversely with angiographic score for patients 
with PAD (Table 6). However, this relationship lost statistical significance after 
adjustment for potential confounders (data not shown) (Paapstel et al. 2018). 
 
Table 7. Multiple regression model for PAD group with resting heart rate as the 
dependent variable. 
Variable Regression 
coefficient 
Standard error p-value 
LysoPC a C17:0 –7.962 2.302 0.002 
Glucose 9.192 3.110 0.006 
Mean arterial pressure 0.309 0.138 0.033 
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aR2=0.388, p=0.001. bR2=0.300, p=0.005. cR2=0.273, p<0.001. dR2=0.162, p=0.009. PAD, 
peripheral arterial disease; CAD, coronary artery disease; ADMA, asymmetric dimethylarginine; 
Arg, arginine; lysoPC, lysophosphatidylcholine; LDL-C, low-density lipoprotein cholesterol. 
LysoPC a C20:4, lysoPC a C18:0, mean age, body mass index, mean arterial pressure, 
interleukin-6, total cho-lesterol, LDL-C, glucose, resistin, platelet count, antihypertensive 
treatment and statin use were entered as independent variables into the regression models. 
 
 
5.3.3. Glycerophospholipids in relation to biochemical parameters 
After adjusting for multiple comparisons, the following relationships were found 
(Table 6). LysoPC a C16:0 showed a positive correlation with total cholesterol 
and inverse correlations with interleukin-6 and high-sensitivity C-reactive 
protein for patients with PAD; it also showed positive correlations with total 
cholesterol and low-density lipoprotein cholesterol for patients with CAD. 
LysoPC a C17:0 was inversely correlated with interleukin-6 and high-sensitivity 
C-reactive protein for the patients with PAD; it also correlated negatively with 
interleukin-6 and insulin for the CAD and control groups, respectively. LysoPC 
a C18:0 showed positive correlations with total cholesterol, low-density 
Table 8. Multiple regression analyses for the PAD and CAD patients with ADMA/Arg 
and ADMA as dependent variables. 
Variable Regression 
coefficient 
Standard error p-value 
PAD patients    
ADMA/Arga
    LysoPC a C20:4 –0.0002 6.7–5 0.006 
Mean arterial pressure 4.6–5 1.7–5 0.012 
    LDL-C 0.0004 0.0002 0.025 
ADMAb    
    LysoPC a C20:4 –0.024 0.009 0.010 
    LDL-C –0.034 0.023 0.155 
Mean age 0.002 0.003 0.426 
CAD patients    
ADMA/Argc    
Platelets –9.7–6 3.0–6 0.005 
Interleukin-6 7.4–5 2.6–5 0.008 
LysoPC a C18:0 –4.9–5 2.1–5 0.022 
ADMAd    
Resistin 0.031 0.012 0.010 
LysoPC a C18:0 –0.004 0.002 0.013 
LDL-C 0.028 0.016 0.086 
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lipoprotein cholesterol, and high- density lipoprotein cholesterol and inverse 
correlations with interleukin-6, high-sensitivity C-reactive protein, and insulin 
for the PAD group; it showed positive correlations with total cholesterol and 
low-density lipoprotein cholesterol and an inverse correlation with interleukin-6 
for the CAD group; for the healthy controls, it correlated inversely with insulin. 
LysoPC a C20:4 correlated negatively with interleukin-6 for patients with PAD; 
it showed a positive correlation with high-density lipoprotein cholesterol and an 
inverse correlation with insulin for the healthy subjects. PC aa C32:2 correlated 
positively with total cholesterol and low-density lipoprotein cholesterol and 
inversely with interleukin-6 only for the PAD group (Paapstel et al. 2018). 
 
 
5.3.4. The comparative analysis of metabolite levels in patients with 
plaque psoriasis, atopic dermatitis and atherosclerosis. 
Targeted analysis of the same metabolites and metabolite ratios were used in the 
study on psoriasis (Paper I), atopic dermatitis (Paper II) and atherosclerosis 
(Paper III) which makes their results comparable to each other. When comparing 
the metabolomic profiles of PS and AD no metabolites were discovered to be 
statistically significantly different although three metabolite ratios namely 
X.C2.C3...C0, C2...C0 and Total.AC...C0 were downregulated in PS and AD 
when compared to controls. The concentration levels of statistically significant 
phosphatidylcholines in PS and AD were found to be statistically not significant 
in atherosclerosis patients and vice versa.  
  
6. DISCUSSION 
6.1. The metabolomic profile of plaque psoriasis  
The metabolomic profiles of patients with plaque psoriasis differ significantly 
from controls as evidenced by the multitude of discovered metabolites, the 
generated principal component analysis figures where the clustering of samples 
can be noted and the statistical models used to classify samples in Paper I. 
Many of the discovered metabolites, namely Glu, Orn and Phe were amino 
acids, which had elevated levels in plaque psoriasis patients thus confirming the 
results of similar studies where perturbations in the amino acid profile were 
noted (Kamleh et al. 2015; Kang et al. 2017). Due to the nature of plaque 
psoriasis, keratinocyte proliferation is upregulated and therefore the increase in 
the biosynthesis of proteins is necessary, which may account for the increase in 
amino acid levels. Similarly to Kang et al. some amino acids and their ratios 
(Orn, Putrescine...Orn) were indicative of changes in the urea cycle of psoriatic 
patients. The urea cycle leads to the polyamine synthesis pathway, the products 
of which can stimulate cell proliferation (Wei et al. 2001).  
Plaque psoriasis is an inflammatory disease and a constant inflammation can 
lead to oxidative stress in the body. Increased levels of methioninesulfoxide and 
phytol were discovered in plaque psoriasis patients, which is a direct indication 
of oxidative stress (Brot and Weissbach 2000; Leipnitz et al. 2010). Arguably 
the altered levels of phosphatidylcholine levels are also indicative of oxidative 
damage in the organism. However, due to the novelty of lipidomics, it is not 
determined yet whether the up- or downregulation of certain PCs is highly 
specific and indicative of a condition or whether a change in an organism affects 
many PCs simultaneously and the changes seen vary among individuals. 
In plaque psoriasis patients the decrease in acylcarnitine levels like C9, C12, 
C10.2, C7.DC and ratios C2...C0, X.C2.C3...C0 and [C16 + C18]/C0 hint at 
changes in overall β-oxidation activity, and it could be argued that the levels 
decrease due to the increased energy consumption and fatty acid oxidation. The 
increased activity of carnitine palmitoyltransferase-1, which is responsible for 
the rate of transport of long-chain fatty acids into mitochondria has been 
demonstrated in lesional skin (Caspary et al. 2005).  
The random forest statistical model that was trained on data from targeted 
analysis achieved 0.86 AUC, 0.77 sensitivity and 0.74 specificity averaged 
across five repetitions. The results are promising and if the number of partici-
pants increased then a better model could be trained and perhaps one day it 
could be applied in clinical medicine to help with the diagnosis of plaque 
psoriasis. However, the amount of data needs to increase beforehand as well as 
the data on other diseases incorporated into the model for a useful predictive 
model capable of differential diagnosis.   
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6.2. The metabolomic profile of atopic dermatitis  
The analyzed metabolomic profiles of atopic dermatitis patients were rather 
similar to controls when looking at PCA figures where the clustering of cases 
and controls overlapped quite noticeably. Using classical statistical methods, 
however, a number of metabolites emerged as seen in Paper II. AD patients 
showed lower levels of acylcarnitine and a number of carnitine ratios, which are 
all indicative of a suppressed β-oxidation pathway. A study conducted on mice 
showed that this might lead to lipid accumulation in the liver (Seino et al. 2012) 
although a similar study in humans to assess the lipid contents of liver in 
patients with AD is yet to be conducted. To compensate for the suppression of 
the β-oxidation, other pathways have to be upregulated. In our study on AD we 
found higher levels of Total.AC.DC. . .Total.AC, which could be indicative of 
β-oxidation dysregulation, whereas other studies have reported the upregulation 
of anaerobic glycolysis through the rise of lactate levels in AD patients (Assfalg 
et al. 2012). It is worth pointing out however that in AD patients only a slight 
inhibition of β-oxidation is probable and not the complete lack of it.  
The datasets from targeted and untargeted analysis in the AD study were 
subjected to statistical analysis using three different machine learning models, 
namely glmnet, pda and rf. In targeted analysis, machine-learning models 
achieved an average performance close to 75% whereas for untargeted analysis 
all three machine-learning models showed high accuracy (~90%) on all three 
modes (negative, positive and combined). Repeated cross-validation technique 
was used but the same conclusions apply here as were with PS study in Paper I 
that a larger cohort is needed before a predictive model can be applied in a 
clinical setting to better help diagnose atopic dermatitis.  
 
The serum profiles of patients with atherosclerosis were altered in comparison 
to controls as evidenced by the numerous PCs and LPC that emerged as a result 
of statistical tests. Interestingly, the coefficients of Spearman’s rank correlation 
between clinical characteristics and selected glycerophospholipids for the three 
study groups showed similarities in the correlations but were not identical in 
regards to PCs and a correlating characteristics. This raises the hope that PCs 
and LPCs are specifically dependent on external and internal stimuli and 
changes in their serum levels have not happened by chance but more specifi-
cally tied to certain conditions and events.  
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6.3. The analysis of serum phosphatidylcholines and 
lysophosphatidylcholines in patients with coronary  
artery disease and peripheral artery disease 
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In this thesis, the metabolomic profiles of patients with plaque psoriasis and 
atopic dermatitis were explored using targeted and untargeted methods. 
Targeted analysis was done using the AbsoluteIDQTM p180 kit (BIOCRATES 
Life Sciences AG, Innsbruck, Austria), which uses isotopic internal standards 
and quality controls for the exact quantification of metabolites while untargeted 
analysis used two different mass-spectrometers and methods. The targeted 
method uses isotopic internal standards for the exact quantification of a handful 
of metabolites and quality controls for the normalization in variation of signal 
intensities. This allows to compare samples that are measured at different time-
points while still remaining comparable despite the variation in the performance 
of the machine. The data from different untargeted methods used to measure 
psoriasis and atopic dermatitis samples can still provide insight into the 
similarities and differences of the two diseases, but the comparison is not 
exhaustive and fully overlapping.  
 
Using the targeted analysis method, 3 metabolite ratios were all discovered to 
be downregulated in both psoriasis and atopic dermatitis when compared to 
controls, namely ratios of acylcarnitine to free carnitine (C2...C0), short-chain 
acylcarnitines to free carnitine (X.C2.C3...C0), and esterifed carnitine to free 
carnitine (Total.AC...C0). Carnitine can either have an endogenous origin where 
it is synthesized from lysine and methionine (Kanehisa 2000) or exogenous 
origin from dietary sources that accounts for up to 75% of carnitine (Rebouche 
1992). Acylcarnitines are fatty acid and carnitine esters formed in the cytosol to 
transport fatty acids into the mitochondrial matrix for β-oxidation and for the 
structural maintenance of the cell membrane (Famularo et al. 1997). The liver is 
mostly responsible for the synthesis of various acylcarnitines and they are 
transported throughout the body for energy production where needed (Xu et al. 
2016). The three downregulated ratios are all indicators of overall β-oxidation 
activity meaning that the metabolites central in β-oxidation (acetyl-CoA and 
propionyl-CoA) have lower levels in PS and AD serum when compared to 
controls. This in turn means that less ATP is produced through β-oxidation as 
has been demonstrated in mice with AD by Seino et al (Seino et al. 2012). To 
compensate the defective β-oxidation and the accumulation of lipids in the 
cytosol, ω-oxidation has been upregulated in AD patients, indicated by the 
higher level of fraction of dicarboxylic acylcarnitines of the total acylcarnitines 
(Total.AC.DC. . .Total.AC) discovered in Paper II. The change was not found to 
be significant for psoriasis. 
6.4. The comparative metabolomic analysis of plaque 
psoriasis and atopic dermatitis 
6.4.1. The similarities in the metabolomic profile of psoriasis and 
atopic dermatitis 
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Several differences in metabolite profiles were noted when comparing the 
results from the serum metabolomic analysis of psoriasis and atopic dermatitis 
patients. Most notably, the metabolomic profile of psoriasis shows an increase 
in several circulating amino acids. The levels of glutamate (Glu), ornithine 
(Orn) and phenylalanine (Phe) are all upregulated in psoriasis samples while the 
ratios of citrulline to ornithine (Cit...Orn) and putrescine to ornithine 
(Putrescine...Orn) are downregulated. The increased serum levels of the three 
amino acids can be associated with a higher demand for amino acids in the 
hyperproliferative epidermis, where de novo synthesis of proteins is upregulated 
and the rate of mitosis in basal keratinocytes is increased compared to non-
lesional skin (Nestle, Kaplan, and Barker 2009). Cit...Orn is lower in psoriasis 
patients, which indicates the lower activity of ornithine carbamoyltransferase 
and the accumulation of ornithine. Additionally, Putrescine...Orn is lower in 
psoriasis patients showing a reduction in the activity of ornithine decarboxylase 
(EC 4.1.1.17) and to overall changes in the urea cycle, which is concordant with 
a similar study on urea cycle intermediates in psoriasis (Kang et al. 2017).  
Methioninesulfoxide (Met.SO) is the oxidized form of methionine that reacts 
with free radicals and goes through the oxidation process (Brot and Weissbach 
2000). Met.SO and the ratio for the fraction of sulfoxidized methionine of the 
unmodified methionine pool both had elevated concentrations in psoriasis 
patient serums, which is indicative of oxidative stress. 
While both PS and AD have similar changes in multiple acylcarnitine ratios, 
both diseases show a reduction in concentrations of different acylcarnitines. PS 
has decreased levels of nonaylcarnitine (C9), pimelylcarnitine (C7.DC), dodec-
anoylcarnitine (C12) and decadienylcarnitine (C10.2) while AD has a lower 
level for acetylcarnitine (C2). The lower levels of various acylcarnitines have 
been associated with insulin resistance (Bailin et al. 2018), which can be 
associated with a higher prevalence of metabolic syndrome in PS (Milčić et al. 
2017) and AD patients (Lee et al. 2017).  
The multiple phospholipids that are up- or downregulated in PS and AD are 
all different, but due to the high number of endogenous phosphatidylcholines 
(PCs) it is unclear what the functions of different PCs are beyond functioning as 
building blocks in cell membranes.  
Untargeted analysis revealed more disease specific metabolites in addition to 
the expected changes in phospholipids. Urea was found to be of higher 
concentration in psoriasis samples, which correlates well with the changes 
found in urea cycle related metabolites. The urea cycle leads to the polyamine 
synthesis pathway, which can stimulate cell proliferation such as keratinocyte 
expansion, a part of keratinocytosis in psoriasis (Wei et al. 2001). The require-
ment of polyamines may speed up the mobilization of arginine (an intermediate 
of the urea cycle) from synthesis sites to the epidermis, which can lead to 
elevated levels in serum (Abeyakirthi et al. 2010). AD on the other hand had 
6.4.2. The differences in the metabolomic profile of psoriasis and 
atopic dermatitis 
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higher concentrations for a peptide DSGEGDFXAEGGGVR, which is a 
cleavage peptide of Fibrinogen A-α. The increase in the concentration is not 
specific to atopic dermatitis but has also been seen in tuberculosis (Weiner et al. 
2012), diabetes (Suhre et al. 2010), and Buruli ulcer (Niang et al. 2015). The 
properties of fibrin clot in AD patients were increased in clot mass and fiber 
thickness, and rate of clot formation (Nastałek, Wojas-Pelc, and Undas 2010). 
Another study showed higher cutaneous fibrinolytic activity in the acute phase 
of AD patients (Lotti et al. 1989).  
 
Phosphatidylcholines (PC) belong to a class of phospholipids consisting of 
choline as a headgroup, glycerophosphoric acid and a variety of fatty acids, 
which can either be saturated or unsaturated. The synthesis of PCs in eukaryotes 
includes the condensation reaction of diacylglycerol and cytidine 5’-diphospho-
choline, which is mediated by an enzyme called diacylglycerol cholinephospho-
transferase. In the liver however the synthesis is done step-by-step through the 
methylation of phosphatidylethanolamine with S-adenosyl methionine as the 
methyl group donor (Yeagle 2016). 
Lysophosphatidylcholines (LPC) are produced when a PC molecule is 
partially hydrolyzed mainly by phospholipase A2 and phospholipase A1 (Schmitz 
and Ruebsaamen 2010), hepatic secretion (Sekas et al. 1985) or lecithin-
cholesterol acyltransferase (Subbaiah et al. 1980). PCs have long been thought 
of as being merely cell membranes components, but other functions have recently 
emerged. For instance, PCs may act as natural surfactants, blood lipoproteins 
and bile (Furse and de Kroon 2015). Additionally, PCs act as a reservoir for 
fatty acids (arachidonic acid, docosahexanoic acid) that are used as precursors 
for lipid-derived signaling molecules. More specifically, arachidonic acid can 
form inflammatory prostanoids whereas anti-inflammatory and homeostatic 
prostanoids are derived from ω-3 unsaturated fatty acids. This affects allergy, 
asthma and systemic inflammation (Wymann and Schneiter 2008). LPCs have 
many biological roles involved in endothelial dysfunction, monocyte recruit-
ment, vascular smooth muscle cell proliferation (Park et al. 2015). Since the 
biological roles of PCs and LPCs are so vast it is difficult to pinpoint their cause 
and effect in atherosclerosis. In mice however a higher uptake of dietary 
phosphatidylcholine led to higher concentrations of trimethylamine N-oxide 
(TMAO), choline and betaine, all of which were later associated with a higher 
risk for CVD in human patients (Wang et al. 2011). Another study found 10 
alkenylphosphatidylcholine species and 6 alkyl-phosphatidylcholines that were 
negatively correlated with myocardial infarction incidence after the adjustment 
for traditional risk factors and correction for multiple testing (Moxon et al. 
2017). The PCs found in Paper III are also correlated with atherosclerosis, 
which hints at the causative effect of PCs in CVDs. Interestingly, the three PCs 
found in targeted plaque psoriasis analysis (Paper I), namely PC.ae.C38.0, 
 
6.5. Phosphatidylcholines and their role in atherosclerosis 
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PC.ae.C40.6, PC.aa.C36.5, and the PCs that were discovered to be statistically 
significantly different in the targeted analysis of atopic dermatitis (Paper II), 
namely PC.aa.C38.5 and PC.aa.C40.5 were all lower in concentrations for PS 
and AD than controls, similarly to the PCs found in Paper III that were also 
lower in cases than controls – lysoPC.a.C18:2, PC.aa.C28:1, PC.aa.C30:0, 
PC.aa.C32:2, PC.ae.C30:0 and PC.ae.C34:2. However no overlap in the exact 
PCs was noted and the PCs found in PS and AD analysis were not statistically 
significant in patients with PAD and CAD. This can be explained by the 
difference in cohorts, their comorbidities and disease-specific risk factors. 
These findings might also imply that multiple PCs affect the cardiovascular 
health of patients and finding just a handful of PCs that are solely responsible or 
indicative of CVDs is not likely. The other PCs found in the untargeted analysis 
of PS and AD patients were either not measured or statistically not significantly 
changed in patients with PAD or CAD.   
 
 
6.6. Psoriasis, atopic dermatitis and their association  
with a higher risk for cardiovascular diseases 
Psoriasis is a chronic immune-mediated inflammatory disease that has been 
associated with coronary artery disease (CAD) (Prey et al. 2010). Psoriasis in 
combination with other cardiovascular (CV) risk factors can lead to an 
increased incidence of CAD (Shaharyar et al. 2014; Joel M. Gelfand et al. 
2006). A more recent study shed light on whether psoriasis might increase the 
chance for CAD as an independent variable where the patients and controls 
were carefully selected to not be influenced by other common CAD risk factors 
such as arterial hypertension, chronic kidney disease, diabetes mellitus, 
dyslipidemia or smoking. It was noted that patients with psoriasis had higher 
values for arterial stiffness and lower values for global longitudinal strain, 
which can both be associated with a higher risk for CAD (Dattilo et al. 2018). 
Another study showed that patients with psoriasis have a higher prevalence and 
incidence for common CV risk factors including hypertension, obesity, diabetes 
and hyperlipidemia (Radner et al. 2017). The combination of psoriasis as an 
independent cofactor and traditional CV risk factors may therefore act 
synergistically to increase the prevalence of CAD. Several metabolites that 
could contribute to CV risk were found in Paper I, including methionine-
sulfoxide, phosphatidylcholines and phytol. It can be argued that the altered 
levels of the discovered metabolites are the effect of psoriasis and not the cause 
explained by their exogenous origin. In Paper I we found several amino acids 
the levels of which differed from controls, which were implicated in the urea 
cycle. These findings have been confirmed by other studies (Kang et al. 2017; 
Kamleh et al. 2015) but the association can be more likely explained by the 
hyperproliferation of the skin rather than these altered metabolite levels 
constituting CV risk factors.  
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The higher risk for cardiovascular diseases in atopic dermatitis patients 
however is not so clear and remains controversial. AD can be linked to a higher 
body mass index (BMI), which is a risk factor for CVD, but it seems that the 
association can also be linked to population differences. For example people 
living in North America or Asia had higher association of AD and BMI whereas 
the European population did not (Silverberg 2016; Zhang and Silverberg 2015). 
To understand the connection of AD with CVD risk a comprehensive meta-
analysis was done, which revealed only a marginally increased risk for PAD, 
hypertension and angina pectoris but an increased risk for myocardial infarction 
or stroke was not noted in patients with AD (Standl et al. 2017). On the other 
hand the increase of proteins that are associated with atherosclerosis 
(fractalkine/CX3CL1, CCL8, M-CSF, HGF), inflammatory mediators (MMP12, 
IL-12/IL-23p40, CXCL9, CCL22, PI3/Elafin), and proteins associated with  
T-cell activation and angiogenesis were upregulated in AD patients (Brunner et 
al. 2017). In Paper II several metabolites were found that could be associated 
with a higher risk for CVD, namely the peptide DSGEGDFXAEGGGVR, 
which can contribute to a faster clot formation, disturbance in the levels of 
phosphatidylcholines that can be associated with systemic inflammation and 
lactate, which has been associated with hypertension (Juraschek et al. 2015). 
Overall it can be said that atopic dermatitis might slightly increase the risk for 
CVD but the association is not as clear or strong as with psoriasis.  
 
 
The present thesis that is based on Papers I–III has several limitations which 
must be acknowledged for a more balanced interpretation of the results. Firstly, 
the number of participants in all of the studies was relatively low, which could 
skew the data and give a distorted view of the results. Secondly, although the 
statistical computational models used in Papers I and II were cross-validated, 
they should be applied to a larger dataset before being implemented in clinical 
practise. Thirdly, care should be taken when extrapolating the results from 
Paper III to women because only men were included in the study. Additionally, 
the recruited men remained on medications and were smokers, which blurs the 
lines of cause and effect.   
6.7. Limitations 
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7. CONCLUSIONS 
1) The metabolomic profiles of psoriasis patient serums were measured using a 
targeted method on a ABSciex QTRAP 4500 mass-spectrometer with an 
AbsoluteIDQTM p180 kit resulting in 19 statistically differing metabolites, 
and an untargeted method on a ABSciex QTRAP 3200, which yielded 22 
metabolites that were statistically significantly different. Data from the 
targeted analysis was used to build computational models that had high 
sensitivity and specificity in classifying samples as cases or controls.  
2) The analysis of data from targeted and untargeted measurements of atopic 
dermatitis patient serums resulted in 13 metabolites that characterize AD. 
The computational models built on the data achieved high precision when 
classifying samples achieving a 75% and 90% rate of accuracy for targeted 
and untargeted data respectively.  
3) The serum levels of phosphatidylcholines and lysophosphatidylcholines in 
patients with coronary artery disease and peripheral artery disease were 
measured and their associations with hemodynamics, endothelial dysfunc-
tion and arterial stiffness were analyzed. Multiple correlations of serum 
metabolite levels to disease severity and progression were discovered  
4) The comparative analysis of serum metabolite levels for psoriasis, atopic 
dermatitis and atherosclerosis resulted in multiple metabolites that differed 
which is indicative of similarities in the underlying inflammatory processes 
of the diseases. The differences in the discovered metabolites point to the 
contrastive pathophysiological mechanisms.  
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SUMMARY IN ESTONIAN 
Psoriaasi, atoopilise dermatiidi ja  
ateroskleroosi metaboloomne profileerimine 
Metaboloomika on teadusharu, mis tegeleb madalmolekulaarsete ühendite 
mõõtmise ja analüüsimisega. Nendeks on aminohapped, biogeensed amiinid, 
süsivesikud, rasvhapped, nukleiinhapped või peptiidid, mis võivad olla nii ekso-
geenset kui ka endogeenset päritolu. Nende ainete samaaegne mõõtmine 
võimaldab näha ainevahetusradade otsest peegeldust, nö. metaboloomset 
sõrmejälge. Selline metaboloomne profileerimine võimaldab klassifitseerida 
proove juhtudeks või kontrollideks ning jälgida seeläbi haiguse intensiivsust ja 
kulgu pärast ravi alustamist. Metaboloomika meetodeid on kasutatud paljudes 
erinevates biomeditsiini-alastes uuringutes sealhulgas ka et uurida vähk-
kasvajaid, südame-veresoonkonnahaigusi, diabeeti ja paljusid teisi. Üldiselt 
saab väita, et metaboloomikas kasutatavad meetodid on osutunud hindamatuks 
paljudes teadusharudes ning on viinud mitmete haigus-spetsiifiliste bioloogiliste 
markerite avastamiseni, mis omakorda on parandanud haiguste diagnoosi ja 
ravi. 
Psoriaas on laialt levinud krooniline põletikuline nahahaigus, mis esineb 
kuni 1%-l lastest ja 2%–3% üldpopulatsioonist. Haiguse teke on seotud mitme 
põhjusega, sealhulgas geneetiline eelsoodumus ja vastuvõtlikkus, keskkonna 
mõjutegurid koos immuunsüsteemi düsfunktsiooni ja nahabarjääri häirega. 
Lisaks märgatavatele muutustele nahas, avaldab haigus mõju ka inimese 
psühholoogilisele ja sotsiaalsele heaolule. Psoriaasi on seostatud ka mitmete 
kaasuvate haigustega, milleks võivad olla diabeet, südame-veresoonkonna-
haigused, põletikulised soolehaigused, metaboolne sündroom, ülekaal ning 
psoriaatriline artriit. 
Atoopiline dermatiit on laialt levinud ja kompleksne nahahaigus, mis 
mõjutab kuni 15% lapsi ja täiskasvanuid üldpopulatsioonis. Kuigi enamik lapsi 
kasvab haigusest välja, hõlmab see teatud juhtudel ka täiskasvanuid, mõjutades 
patsientide heaolu ja põhjustades rida kaasuvaid haigusi, sealhulgas allergiad, 
astma, tähelepanuhäired ning aneemiat.  
Ateroskleroos on põletikuline haigus, hõlmates arterite seinu, kuhu kogu-
nevad põletikulised rakud ja lipiidid. See viib arterite ahenemiseni, mis võib 
päädida trombi tekkega, põhjustades infarkti. Ateroskleroosi kõige levinumad 
vormid on perifeerne arterite haigus ja koronaar-arteri haigus, millest mõlemast 
on saanud suured rahvatervise probleemid.  
 
UURIMUSE EESMÄRGID 
Käesoleva doktoritöö peamiseks eesmärgiks oli analüüsida psoriaasi, atoopilise 
dermatiidi ja ateroskleroosi patsientide metaboloomseid profiile ning hinnata 
sarnasusi ja erinevusi leitud metaboliitides. 
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Uurimuse täpsed eesmärgid olid järgnevad: 
1) Mõõta psoriaasipatsientide metaboloomsed profiilid kasutades suunatud ja 
suunamata metaboloomseid meetodeid ning luua statistilised mudelid, mida 
saaks kasutada haiguse diagnoosimisel ja ravi jälgimisel. 
2) Avastada metaboliidid, mis on iseloomulikud atoopilisele dermatiidile ning 
kasutada statistilisi mudeleid, mis kasutavad andmeid suunatud ja suunamata 
metaboloomilistest mõõtmistest proovide klassifitseerimiseks. 
3) Analüüsida seerumi fosfatidüülkoliinide ja lüsofosfatidüülkoliinide tasemeid 
ning nende seoseid hemodünaamikaga, endoteeli düsfunktsiooniga ning 
arterite jäikusega patsientidel, kellel on diagnoositud koronaar-arterite 
haigus ja perifeerne arterite haigus. 
4) Uurida, kas on sarnasusi metaboliitide tasemetes patsientides, kel on diag-
noositud psoriaas, atoopiline dermatiit ja ateroskleroos 
 
UURINGUTE MEETODID 
Psoriaasiuuringus värvati Tartu Ülikooli Kliinikumis kokku 106 vabatahtlikku, 
atoopilise dermatiidi uuringus 49 uuritavat ning ateroskleroosiuuringus 124 
isikut. Uuritavate vereseerumeid uuriti kasutades mitmeid erinevaid suunatud ja 
suunamata analüüsi meetodeid. Saadud andmetel rakendati klassikalisi statisti-
lisi meetodeid haigust iseloomustavate metaboliitide avastamiseks ning loodi 
mitmeid erinevaid statistilisi mudeleid juhtude ja kontrollide klassifitseeri-
miseks.  
 
TULEMUSED JA JÄRELDUSED 
1) Psoriaasipatsientide metaboloomsed profiilid mõõdeti kasutades suunatud 
meetodit ABSciex QTRAP 4500 mass-spektromeetril rakendades 
AbsoluteIDQTM p180 analüüsikomplekti ja suunamata meetodit kasutades 
ABSciex QTRAP 3200 mass-spektromeetrit. Tulemusena leiti suunatud 
analüüsist 19 ja suunamata analüüsist 22 statistiliselt oluliselt erinevat meta-
boliiti. Andmeid, mis saadi suunatud analüüsist, kasutati arvutuslike statisti-
liste mudelite ehitamiseks, millel oli kõrge sensitiivsus ja spetsiifilisus 
proovide klassifitseerimisel juhuks või kontrolliks. 
2) Atoopilise dermatiidiga patsientide vereseerumite uurimine päädis 13 
erineva metaboliidi avastamisega suunatud ja suunamata analüüsist, mis 
iseloomustavad atoopilist dermatiiti. Arvutuslikud statistilised mudelid 
saavutasid head tulemused proovide klassifitseerimisel andes 75% ja 90% 
täpsused vastavalt suunatud ja suunamata analüüsi andmetest. 
3) Vereseerumi fosfatidüülkoliinide ja lüsofosfatidüülkoliinide tasemeid mõõdeti 
patsientides, kellel oli diagnoositud koronaar-arterite haigus ja perifeerne 
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arterite haigus ning tulemusi analüüsiti seoses hemodünaamikaga, endoteeli 
düsfunktsiooniga ning arterite jäikusega. Avastati mitmeid seoseid seerumi 
metaboliitide tasemete ja haiguse tõsiduse ja edenemise vahel.  
4) Psoriaasi, atoopilise dermatiidi ja ateroskleroosi võrdlev analüüs viis mitmete 
metaboliitide avastamiseni, viitamaks sarnasustele erinevate haiguste 
põletikulises olemuses samas kui erinevused metaboliitides viitavad 
haiguste erinevatele patofüsioloogiatele.  
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